[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Orthofix, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":91},{"warningLetters":4,"total":90},[5,31,49,67],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},703,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-19T04:00:00Z\">08\u002F19\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiach-orthopaedics-709827-08192025\">Miach Orthopaedics \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick McBrayer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Miach Orthopaedics \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>69 Milk St Ste 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Westborough\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01581\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pmcbrayer@miachortho.com\"> pmcbrayer@miachortho.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 709827\u003C\u002Fp>\u003Cp>August 19, 2025\u003C\u002Fp>\u003Cp>Dear Mr. McBrayer:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Westborough, MA from March 31, 2025 through April 23, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Bridge-Enhanced ACL Restoration (BEAR) Implant intended for the treatment of anterior cruciate ligament (ACL) injuries. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation Violation(s)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Ms. Rita Paparazzo, Vice President of Quality, Regulatory, and Clinical Affairs, dated May 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audits conducted as a process monitoring activity to ensure that the specified sterility assurance level (SAL) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your firm’s validated E-Beam sterilization process continues to be met for your BEAR Implant devices, is inadequate. The rationale dated 8\u002F2\u002F23 to only use \u003Cstrong>(b)(4)\u003C\u002Fstrong> during sterility testing to recover microorganisms from the BEAR Implant devices and remove the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to detect the presence of anaerobes on the basis that section A.6.1.1 of ISO 11737-1 states “***\u003Cem>If evaluation has shown that testing for anaerobes is not indicated, then this test can be eliminated in the future\u003C\u002Fem>***” and section 6.7 of ISO 11737-2 states “***\u003Cem>Culture conditions shall be selected after consideration of the types of microorganisms expected to be present. The results of this consideration and the rationale for the decisions reached shall be recorded\u003C\u002Fem>***” is unsubstantiated because your historical \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audit data for sterility testing shows that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was unable to detect the presence of a strict anaerobe, \u003Cem>Tissierella Praeacuta\u003C\u002Fem>, which was found to only be present in \u003Cstrong>(b)(4)\u003C\u002Fstrong> during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audit on 10\u002F7\u002F22 (STR-095-006, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Similarly, the results of other \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audits have shown that facultative anaerobes such as \u003Cem>Bacillus licheniformis\u003C\u002Fem> and \u003Cem>Bacillus megaterium\u003C\u002Fem> were only detected in \u003Cstrong>(b)(4)\u003C\u002Fstrong> but not \u003Cstrong>(b)(4)\u003C\u002Fstrong> despite sampling from the same Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Hence, the rationale to eliminate \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterility testing from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audits is not valid due to examples which demonstrate that \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked the sensitivity to detect both strict and\u002For facultative anaerobes on the BEAR Implant devices.\u003C\u002Fp>\u003Cp>Moreover, your decision to only use \u003Cstrong>(b)(4)\u003C\u002Fstrong> conflicts with the recommendation from your microbiologist consultant on 10\u002F26\u002F21 (TR-21-12-10) for “***\u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterility testing of verification dose samples\u003C\u002Fem>***” and section 5.2.2 of STR-095-006 which states \u003Cstrong>(b)(4)\u003C\u002Fstrong> is for recovering aerobes and \u003Cstrong>(b)(4)\u003C\u002Fstrong> is for recovering anaerobes.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-002, the immediate corrections included quarantining and discarding lot numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Starting with Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to re-implement use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for bioburden monitoring of facultative and strict anaerobic microorganisms. In addition, you plan to review bioburden data for 12 months and assess whether use of both media still remains appropriate; establish a new procedure for bioburden monitoring to align with the contract manufacturer’s procedure; revise the process validation procedure to ensure that validated parameters are properly monitored; review all other process validations for the BEAR Implant devices; and revise relevant work instructions as needed to ensure that the validated parameters are properly monitored. However, no timelines were provided for these corrections and\u002For corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to implement sections 1.0 and 4.2 of your “Nonconforming Materials and Processes” procedure (SOP-0017; Rev. B; Effective: 4\u002F12\u002F23) which state “***\u003Cem>products that do not conform to specification requirements are identified, segregated, investigated and dispositioned\u003C\u002Fem>***” and describe the steps for initiation of a nonconformance report, respectively. For example, you did not generate nonconformance reports when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audit reports for your BEAR Implant devices indicated that Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> exceeded the product requirement specification (PRS) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average) (PRS-001; Rev. F; Effective: 7\u002F10\u002F23 – 12\u002F7\u002F23) at \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average) and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> exceeded the PRS of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average) (PRS-001; Rev. G; Effective: 12\u002F8\u002F23 – 9\u002F18\u002F24) at \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average). Moreover, the lack of initiation of nonconformance reports for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> is inconsistent with past actions to initiate NCR 22-002\u002FCAPA 2022-001 (1\u002F17\u002F22) and CAPA 2022-002 (2\u002F28\u002F22) for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> which also exceeded the limits of bioburden.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-001, your immediate corrections are to document decisions and rationale for past production lots (Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) by 5\u002F31\u002F25; establish procedures for bioburden excursions; review a list of process related nonconformances reported to the firm by the contract manufacturer by 5\u002F31\u002F25; and revise the quality agreement with the contract manufacturer (if needed). In addition, you plan to revise the nonconforming product procedure to describe how to evaluate and disposition devices with bioburden excursions and positive tests for sterility by 5\u002F31\u002F25. However, timelines were only provided for some actions and not others. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient and a mechanism for addressing incomplete, ambiguous, or conflicting requirements, as required by 21 CFR 820.30(c).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement the instructions in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) which requires you to consider areas such as performance and intended use, reliability, and safety when identifying user needs and\u002For design input requirements for your resorbable BEAR Implant devices intended to treat anterior cruciate ligament (ACL) injuries. For example, your DCR 2021-011 for the BEAR Implant device lacks user need(s) such as (but not limited to) the need for the implant to achieve full absorption of blood (i.e., hydration) without the use of copious volumes of blood in a timely manner, all while remaining intact.\u003C\u002Fp>\u003Cp>In addition, because the aforementioned user need(s) are absent from the DCR 2021-011 for the BEAR Implant device, you failed to (1) validate that your BEAR Implant device meets these user needs as a part of your design validation under “BEAR Implant Design Validation Protocol” (TP-20-010; Approved 6\u002F17\u002F25) and (2) adequately implement section 4.5.2 of the “Design Control” procedure (SOP-0001; Rev. E; Effective: 7\u002F8\u002F20) which requires translation of “***\u003Cem>user needs into design inputs and assure the design inputs address***intended use and user needs***functional, performance, and safety requirements\u003C\u002Fem>***” and resolution of ambiguous or conflicting requirements prior to approval. For example:\u003C\u002Fp>\u003Cp>a. The design input \"\u003Cem>The BEAR Implant shall be able to absorb whole blood (autologous blood injected during the surgical process)\u003C\u002Fem>\" (9b) in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) is ambiguous because it does not identify parameters (time, volume, technique, etc.) under which the implant must be able to be fully hydrated while remaining intact.\u003C\u002Fp>\u003Cp>Per your instructions for use (IFU) (ML-1002; Rev. H; Effective: 3\u002F2025), the implant “***\u003Cem>is intended to be used with up to 10 ml of autologous blood\u003C\u002Fem>***” and states to “***\u003Cem>hydrate the BEAR Implant with 5-10 mL of non-coagulated autologous blood\u003C\u002Fem>***.” In addition, the “The BEAR® Implant Physeal Sparing Technique” (ML-1274; Rev. A; Effective: 3\u002F2025) describes the technique by which to infuse the implant with blood: “***\u003Cem>Massage the autologous blood into the BEAR Implant, starting with approximately 1mL on the proximal side, then to the sides and finishing with the bottom. Add 1-2mL at a time while massaging the blood in, softening the implant. Once the implant is pliable, inject whole blood into the center of the implant\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>b. The DCR 2021-011 includes design inputs which do not directly address the user need under which they are categorized. For example, the above design input (9b) was inappropriately categorized under the user need (UN-2) of “***\u003Cem>The BEAR Implant must demonstrate non-inferiority in terms of effectiveness when compared with the current standard of care (ACL reconstruction with an autograft) at 2 years post-surgery\u003C\u002Fem>***” and there was no other applicable user need which describes user need(s) of the surgeon such as (but not limited to) the need for the implant to achieve full hydration without the use of copious volumes of blood and absorption of blood in a timely manner, all while remaining intact.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-004, your immediate corrections are to identify a new or existing user need as the basis of the design input “\u003Cstrong>(b)(4)\u003C\u002Fstrong>;” develop a design output specification tied to the new or revised design input; verify that the design output specification meets the design input specification; and develop a test to provide evidence that the new or revised user need is met. Your corrective action is to revise SOP-0001 to require participation of surgeons and other relevant experts in design review for design inputs. However, no timelines were provided for these corrections and\u002For corrective actions. In addition, there were no corrective actions identified to require that surgeons and other experts are included in the development of user needs and to retrospectively review all user needs and design inputs for the BEAR Implant device for any missing user needs, adequacy, and appropriate categorization by user need. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to validate, with a high degree of assurance, that your gelation and lyophilization processes consistently produce BEAR Implant devices which meet the specifications for density (0.062 - 0.072 g\u002Fcm3). For example, although your “Miach BEAR 20510-01 Process Qualification Report” (VAL-08164; Rev. AA; Approved 4\u002F24\u002F24) states that your performance qualification (PQ) demonstrates “***\u003Cem>with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density of the BEAR devices is between \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>***,” this sampling method to use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from \u003Cstrong>(b)(4)\u003C\u002Fstrong> BEAR Implants per lot (Lot #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) does not take into account the impact of an individual implant failing to meet specification, outliers, or standard deviation. Review of the raw data in your PQ revealed that 1 out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the BEAR implants under Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to meet specification (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for density and over \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the density values across lots were at or below the minimum specification, none of which demonstrates a high degree of assurance that your processes result in devices which consistently meet density specifications.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You provided no corrective actions for this deficiency on the basis that an \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an average characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. In addition, confidence intervals based \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plans provide a range within which a value is likely to fall, not a high degree of assurance that a process will produce product that consistently meets specification. Therefore, please provide a response on how you plan to address the above deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, the sampling plan outlined in “7540 Dimensional Inspection” for (FRM-01379; Rev AA) to use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from the first \u003Cstrong>(b)(4)\u003C\u002Fstrong> BEAR Implants per lot to accept lots which meet the density specification (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the premise that the collagen slurry mixture in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing step would have met the homogeneity specification is not based on valid statistical rationale. For example, per your Vice President of Research and Development and Manufacturing, if a single implant fails the density acceptance criteria, it will still be released, so long as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants remain within specification. On the other hand, if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants fails, then density is calculated on every implant within the lot, and all samples that do not meet specification will be treated as a nonconformance and scrapped. However, the rationale for this sampling plan is not based on valid statistical rationale because (1) samples are not taken at random; (2) samples are not based on lot sizes which can be up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> units; (3) individual samples may still fail to meet density specifications, even if the previous collagen slurry specification met the specification for homogeneity; and (4) single implants which do not meet density specifications have the potential to be released if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density specification is met. The practice of releasing product when an individual data point was outside of the specification also constitutes distribution of nonconforming product without valid justification. Your complaint and\u002For corrective and preventive action investigations have determined that the gelation process affects densities such that implants with low densities can cause rapid blood absorption and those with high densities can delay or hinder blood absorption, both of which can render the implant unusable due to disintegration or lack of proper hydration, the result of which is delayed surgery requiring use of a second implant (if available) or impaired \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your hazard analysis (001-003-HZ; Rev. B; Effective: 7\u002F10\u002F23).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Per the response to the process validation observation, which employed the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plan strategy as that used during lot release of product, you provided no corrective actions on the basis that an \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an \u003Cstrong>(b)(4)\u003C\u002Fstrong> characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. Therefore, please provide a response as to how you plan to address the above deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and documented evaluation and selection of potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements, as required by 21 CFR 820.50(a)(1).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement:\u003C\u002Fp>\u003Cp>a. Sections 4 and 18 of your “Supplier Quality Agreement” (Approved 1\u002F27\u002F22) which require you to approve protocols and reports for process, sterilization and inspection\u002Ftest validations performed by the contract manufacturer and “***\u003Cem>provide copies of quality records upon request\u003C\u002Fem>***,” respectively. For example, your contract manufacturer refused to provide unredacted supporting documents, such as the process routers, device history records, and process parameters used to manufacture the BEAR Implant device during the FDA inspection.\u003C\u002Fp>\u003Cp>b. Section 4.8 of your “Supplier Management” (SOP-0025; Rev. D; Effective: 12\u002F8\u002F23) which requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> evaluation of major suppliers using the “Supplier Re-evaluation Form” (FRM-0025). For example, your contract manufacturer of the BEAR Implant device has not been evaluated since May 2023 despite being categorized as a major supplier.\u003C\u002Fp>\u003Cp>c. Section 4.1.1 of SOP-0025 which requires “***\u003Cem>no products or services associated with the QMS are to be purchased from a supplier not on the Approved Supplier List\u003C\u002Fem>***.” For example, your firm’s microbiology consultant who authored “Rationale for Eliminating \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Test of Sterility and Anaerobic Bioburden Monitoring” dated 7\u002F30\u002F23 was not on the Approved Supplier List or evaluated. You have been using this consultant since November 2021.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-007, your immediate correction is to complete the 2024 supplier re-evaluation form for the contract manufacturer and for the consultant and revise the quality agreement to allow alternative methods for reviewing all supporting documentation for process, sterilization, and inspection\u002Ftest validations such as onsite review, establishing a master file with the FDA, or having a 3rd party consultant review the documents. As a part of corrective actions, you plan to perform a gap analysis for the approved supplier list and revise SOP-0025 to allow alternative methods for review of supporting documents. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluations to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 4.3.6 of your “Customer Feedback” procedure (SOP-0027; Rev. B – C; Effective: 6\u002F27\u002F24 and 12\u002F8\u002F23) which requires you to categorize customer feedback as complaints, to be processed by the “Complaint Management” procedure (SOP-0019; Rev. C – D; Effective: 12\u002F8\u002F23 and 4\u002F26\u002F24), when they meet the definition of complaints as defined under section 3 of SOP-0027. For example, your customer feedback descriptions in 3 out of 6 reviewed customer feedback forms, which met the definition of complaints, were classified as “Observations” instead of “Complaints” and, therefore, did not include documented evaluations for medical device reporting (MDR) and investigations per sections 4.2 and 4.3 of SOP-0019, respectively, as evidenced below:\u003C\u002Fp>\u003Cp>a. \u003Cu>CF 2024-006 (6\u002F3\u002F24)\u003C\u002Fu>: BEAR Implant “***\u003Cem>hydrating far too quickly (&lt;10 seconds) and becoming unable to properly implant\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>b. \u003Cu>CF 2024-004 (4\u002F12\u002F24)\u003C\u002Fu>: BEAR Implant “***\u003Cem>hydrated EXTREMELY slow. Took 20 cc and maybe 5 min. Much much much slower than average hydration. Could tell the implant was very dense when the surgeon slid Keith needle into it\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>c. \u003Cu>CF 2023-007 (3\u002F7\u002F23)\u003C\u002Fu>: BEAR Implant “***\u003Cem>it was too dense and seemed not to have a porous side. This happened with two of the implants***He is concerned about the variability between implants of the same lot, and does not like the difficulty he had hydrating it\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-009, your immediate corrections are to process the above incidents as complaints and retrospectively review “observations” since 2021 to ensure that no other complaints were missed. As a part of corrective actions, you plan to provide training to ensure that future customer feedback is evaluated in accordance with SOP-0019 and update the training procedure (SOP-004) to control training in accordance with the risk inherent in the process. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>8. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to adequately implement section 4.2 of your firm's “Corrective and Preventive Action Procedure” (SOP-0014; Rev. C; Effective: 9\u002F8\u002F21) which requires completion of a Field Action Decision Form (FADF) and risk assessment if product in the field may be impacted. For example, the FADF for CAPA 2023-001, initiated on 1\u002F27\u002F23 in response to complaints regarding rapid blood absorption and disintegration of BEAR Implants from Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, concluded that a field action was not required per the results of the Health Hazard Evaluation (HHE) Form (DCR 2019-005; Approved 2\u002F17\u002F23) which determined that the hazard of \"ACL is not fully healed\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was “low risk” when an occurrence rating of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was applied. However, this conclusion conflicted with the original “Internal Memorandum***Risk Assessment” conducted per the “Risk Management Plan – BEAR Implant (Project: 001)” (DCR 2020-008; Rev. B; Effective: 8\u002F27\u002F20) on 1\u002F30\u002F23 which found that the risk for this same hazard \u003Cstrong>(b)(4)\u003C\u002Fstrong> was “Unacceptable” (“further risk reduction or additional risk-benefit is required”) when an occurrence rating of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was applied. Applying this same occurrence level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the HHE would have moved the risk level from “low” to “high” (“Field action is required”). Therefore, you failed to conduct an adequate risk assessment under this CAPA 2023-001 in that the discrepancy in occurrence ratings between the HHE and the “Internal Memorandum*** Risk Assessment” was not resolved prior to completion of the FADF.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You stated that there are no BEAR implants that remain in commercial distribution. Under CAPA 2025-006, your immediate correction is to reopen CAPA 2023-001 for review and reiteration if needed. As a corrective action, you plan to revise SOP-0014 to require that FADFs, Health Hazard Assessments, and Risk Assessments are compared for correlation and completeness and that at least two reviewers are included for the assessments. However, no timelines were provided for these corrective actions. In addition, although you obtained Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> from your sales personnel, no corrective actions were identified to document justification for not reporting a correction and\u002For removal of product from the field, including removals limited to sales personnel, to the FDA. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>9. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fp>\u003Cp>Specifically, during the inspection, your firm presented its MDR procedure titled “Medical Device Reporting,” SOP‐0023, Revision B, dated: 8‐Dec‐2023. For example, after reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>a. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\u003Cp>i. The procedure SOP‐0023, Revision B, does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\u003Cp>ii. There are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” and “serious injury,” nor the definition of “reasonably suggests” found in 21 CFR 803.20(c)(1). The absence of these definitions may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a). Without adequate definitions, your procedure lacks executable instructions or the level of detail needed to ensure timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements.\u003C\u002Fp>\u003Cp>b. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003C\u002Fp>\u003Cp>c. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include the circumstances under which your firm must submit initial 30-day, supplement or follow-up and 5‐day reports and the requirements for such reports.\u003C\u002Fp>\u003Cp>d. The procedure SOP‐0023, Revision B, does not adequately describe how your firm will address documentation and record‐keeping requirements, as required by 21 CFR 803.17(b). Specifically, while Section 4.1.3 of the SOP references retaining data for reportable events, it lacks sufficient detail on how the deliberations and decision-making processes used to determine whether an event is reportable or not is to be documented, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\u003Cp>Your firm’s response dated May 13, 2025 did not address the noted procedural deficiencies as they were not listed on the FDA Form 483.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s BEAR implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>10. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example, the information included for Complaint 2023‐011 reasonably suggests that the patient developed an infection at the site of BEAR implant after falling 4.5 weeks post-surgery. Although the information included for the complaint establishes that the device did not malfunction in that the ACL damage observed was the result of a re‐tear due to the fall, the occurrence of the infection in the area surrounding the implantation reasonably suggests that the device may have been a factor in the serious injury event that necessitated irrigation and antibiotic treatment to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on August 23, 2023; however, no corresponding MDR was received by the FDA.\u003C\u002Fp>\u003Cp>Your firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. However, the response indicated that your firm conducted a reportability evaluation in relation to Observation 9. Upon review, the response did not include any information regarding plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\u003C\u002Fp>\u003Cp>\u003Cstrong>11. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example, the information included for Complaints 2022‐001, 2023‐004 and 2024‐001 reasonably suggests that your firm’s BEAR implant malfunctioned (i.e., improper hydration) while in use. The device is a long‐term implantable device. Generally, malfunctions are reportable if they involve a long-term implant and are likely to cause or contribute to death or serious injury, or the malfunction results in the failure of the device to perform its essential function, thereby compromising its therapeutic effectiveness which could cause or contribute to a death or serious injury. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63858 (Dec. 11, 1995), Comment 12, for more information. We believe an improperly hydrated BEAR implant could compromise its structural integrity and therapeutic function, leading to serious complications that might cause or contribute to a death or serious injury. Therefore, the referenced complaints represent MDR reportable events as defined in 21 CFR 803.3. Your firm became aware of information on September 1, 2022, for Complaint 2022‐001, on February 24, 2023, for Complaint 2023‐004, and on January 11, 2024, for Complaint 2024‐001. However, the FDA has not received an MDR for any of these referenced events.\u003C\u002Fp>\u003Cp>Your firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. The response noted that your firm conducted a reportability evaluation and will submit MDRs for Complaints 2022‐001 and 2024‐001. However, the response does not address Complaint 2023‐004. Additionally, your firm has not provided any information indicating plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 709827” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Rita Paparazzo\u003Cbr>VP of Quality, Regulatory, and Clinical Affairs\u003Cbr>rpaparazzo@miachortho.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick McBrayer\n\nRecipient Title\n\nPresident & CEO\n\nMiach Orthopaedics\n\n69 Milk St Ste 100\n\nWestborough, MA 01581\n\nUnited States\n\npmcbrayer@miachortho.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 709827\nAugust 19, 2025\nDear Mr. McBrayer:\nDuring an inspection of your firm located in Westborough, MA from March 31, 2025 through April 23, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Bridge-Enhanced ACL Restoration (BEAR) Implant intended for the treatment of anterior cruciate ligament (ACL) injuries. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Ms. Rita Paparazzo, Vice President of Quality, Regulatory, and Clinical Affairs, dated May 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\n1. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\nSpecifically, the (b)(4) dose audits conducted as a process monitoring activity to ensure that the specified sterility assurance level (SAL) of (b)(4) of your firm’s validated E-Beam sterilization process continues to be met for your BEAR Implant devices, is inadequate. The rationale dated 8\u002F2\u002F23 to only use (b)(4) during sterility testing to recover microorganisms from the BEAR Implant devices and remove the use of (b)(4) to detect the presence of anaerobes on the basis that section A.6.1.1 of ISO 11737-1 states “***If evaluation has shown that testing for anaerobes is not indicated, then this test can be eliminated in the future***” and section 6.7 of ISO 11737-2 states “***Culture conditions shall be selected after consideration of the types of microorganisms expected to be present. The results of this consideration and the rationale for the decisions reached shall be recorded***” is unsubstantiated because your historical (b)(4) dose audit data for sterility testing shows that (b)(4) was unable to detect the presence of a strict anaerobe, Tissierella Praeacuta, which was found to only be present in (b)(4) during a (b)(4) dose audit on 10\u002F7\u002F22 (STR-095-006, Lot # (b)(4)). Similarly, the results of other (b)(4) dose audits have shown that facultative anaerobes such as Bacillus licheniformis and Bacillus megaterium were only detected in (b)(4) but not (b)(4) despite sampling from the same Lot # (b)(4) and Lot # (b)(4). Hence, the rationale to eliminate (b)(4) for sterility testing from the (b)(4) dose audits is not valid due to examples which demonstrate that (b)(4) lacked the sensitivity to detect both strict and\u002For facultative anaerobes on the BEAR Implant devices.\nMoreover, your decision to only use (b)(4) conflicts with the recommendation from your microbiologist consultant on 10\u002F26\u002F21 (TR-21-12-10) for “***(b)(4) for sterility testing of verification dose samples***” and section 5.2.2 of STR-095-006 which states (b)(4) is for recovering aerobes and (b)(4) is for recovering anaerobes.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-002, the immediate corrections included quarantining and discarding lot numbers (b)(4) through (b)(4). Starting with Lot # (b)(4), you plan to re-implement use of (b)(4) for bioburden monitoring of facultative and strict anaerobic microorganisms. In addition, you plan to review bioburden data for 12 months and assess whether use of both media still remains appropriate; establish a new procedure for bioburden monitoring to align with the contract manufacturer’s procedure; revise the process validation procedure to ensure that validated parameters are properly monitored; review all other process validations for the BEAR Implant devices; and revise relevant work instructions as needed to ensure that the validated parameters are properly monitored. However, no timelines were provided for these corrections and\u002For corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nYou failed to implement sections 1.0 and 4.2 of your “Nonconforming Materials and Processes” procedure (SOP-0017; Rev. B; Effective: 4\u002F12\u002F23) which state “***products that do not conform to specification requirements are identified, segregated, investigated and dispositioned***” and describe the steps for initiation of a nonconformance report, respectively. For example, you did not generate nonconformance reports when the (b)(4) dose audit reports for your BEAR Implant devices indicated that Lot # (b)(4) exceeded the product requirement specification (PRS) of (b)(4) CFU\u002Fdevice (average) (PRS-001; Rev. F; Effective: 7\u002F10\u002F23 – 12\u002F7\u002F23) at (b)(4) CFU\u002Fdevice (average) and Lot # (b)(4) exceeded the PRS of (b)(4) CFU\u002Fdevice (average) (PRS-001; Rev. G; Effective: 12\u002F8\u002F23 – 9\u002F18\u002F24) at (b)(4) CFU\u002Fdevice (average). Moreover, the lack of initiation of nonconformance reports for Lot # (b)(4) and Lot # (b)(4) is inconsistent with past actions to initiate NCR 22-002\u002FCAPA 2022-001 (1\u002F17\u002F22) and CAPA 2022-002 (2\u002F28\u002F22) for Lot # (b)(4) and Lot # (b)(4) which also exceeded the limits of bioburden.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-001, your immediate corrections are to document decisions and rationale for past production lots (Lot # (b)(4) and (b)(4)) by 5\u002F31\u002F25; establish procedures for bioburden excursions; review a list of process related nonconformances reported to the firm by the contract manufacturer by 5\u002F31\u002F25; and revise the quality agreement with the contract manufacturer (if needed). In addition, you plan to revise the nonconforming product procedure to describe how to evaluate and disposition devices with bioburden excursions and positive tests for sterility by 5\u002F31\u002F25. However, timelines were only provided for some actions and not others. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient and a mechanism for addressing incomplete, ambiguous, or conflicting requirements, as required by 21 CFR 820.30(c).\nSpecifically, you failed to implement the instructions in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) which requires you to consider areas such as performance and intended use, reliability, and safety when identifying user needs and\u002For design input requirements for your resorbable BEAR Implant devices intended to treat anterior cruciate ligament (ACL) injuries. For example, your DCR 2021-011 for the BEAR Implant device lacks user need(s) such as (but not limited to) the need for the implant to achieve full absorption of blood (i.e., hydration) without the use of copious volumes of blood in a timely manner, all while remaining intact.\nIn addition, because the aforementioned user need(s) are absent from the DCR 2021-011 for the BEAR Implant device, you failed to (1) validate that your BEAR Implant device meets these user needs as a part of your design validation under “BEAR Implant Design Validation Protocol” (TP-20-010; Approved 6\u002F17\u002F25) and (2) adequately implement section 4.5.2 of the “Design Control” procedure (SOP-0001; Rev. E; Effective: 7\u002F8\u002F20) which requires translation of “***user needs into design inputs and assure the design inputs address***intended use and user needs***functional, performance, and safety requirements***” and resolution of ambiguous or conflicting requirements prior to approval. For example:\na. The design input \"The BEAR Implant shall be able to absorb whole blood (autologous blood injected during the surgical process)\" (9b) in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) is ambiguous because it does not identify parameters (time, volume, technique, etc.) under which the implant must be able to be fully hydrated while remaining intact.\nPer your instructions for use (IFU) (ML-1002; Rev. H; Effective: 3\u002F2025), the implant “***is intended to be used with up to 10 ml of autologous blood***” and states to “***hydrate the BEAR Implant with 5-10 mL of non-coagulated autologous blood***.” In addition, the “The BEAR® Implant Physeal Sparing Technique” (ML-1274; Rev. A; Effective: 3\u002F2025) describes the technique by which to infuse the implant with blood: “***Massage the autologous blood into the BEAR Implant, starting with approximately 1mL on the proximal side, then to the sides and finishing with the bottom. Add 1-2mL at a time while massaging the blood in, softening the implant. Once the implant is pliable, inject whole blood into the center of the implant***.”\nb. The DCR 2021-011 includes design inputs which do not directly address the user need under which they are categorized. For example, the above design input (9b) was inappropriately categorized under the user need (UN-2) of “***The BEAR Implant must demonstrate non-inferiority in terms of effectiveness when compared with the current standard of care (ACL reconstruction with an autograft) at 2 years post-surgery***” and there was no other applicable user need which describes user need(s) of the surgeon such as (but not limited to) the need for the implant to achieve full hydration without the use of copious volumes of blood and absorption of blood in a timely manner, all while remaining intact.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-004, your immediate corrections are to identify a new or existing user need as the basis of the design input “(b)(4);” develop a design output specification tied to the new or revised design input; verify that the design output specification meets the design input specification; and develop a test to provide evidence that the new or revised user need is met. Your corrective action is to revise SOP-0001 to require participation of surgeons and other relevant experts in design review for design inputs. However, no timelines were provided for these corrections and\u002For corrective actions. In addition, there were no corrective actions identified to require that surgeons and other experts are included in the development of user needs and to retrospectively review all user needs and design inputs for the BEAR Implant device for any missing user needs, adequacy, and appropriate categorization by user need. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you failed to validate, with a high degree of assurance, that your gelation and lyophilization processes consistently produce BEAR Implant devices which meet the specifications for density (0.062 - 0.072 g\u002Fcm3). For example, although your “Miach BEAR 20510-01 Process Qualification Report” (VAL-08164; Rev. AA; Approved 4\u002F24\u002F24) states that your performance qualification (PQ) demonstrates “***with (b)(4), the (b)(4) density of the BEAR devices is between (b)(4)***,” this sampling method to use the (b)(4) density from (b)(4) BEAR Implants per lot (Lot #: (b)(4); and (b)(4)) does not take into account the impact of an individual implant failing to meet specification, outliers, or standard deviation. Review of the raw data in your PQ revealed that 1 out of (b)(4) of the BEAR implants under Lot # (b)(4) failed to meet specification ((b)(4)) for density and over (b)(4) of the density values across lots were at or below the minimum specification, none of which demonstrates a high degree of assurance that your processes result in devices which consistently meet density specifications.\nWe reviewed your firm’s response and conclude that it is not adequate. You provided no corrective actions for this deficiency on the basis that an (b)(4) sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an average characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the (b)(4) density from the (b)(4) lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. In addition, confidence intervals based (b)(4) sampling plans provide a range within which a value is likely to fall, not a high degree of assurance that a process will produce product that consistently meets specification. Therefore, please provide a response on how you plan to address the above deficiency.\n5. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\nSpecifically, the sampling plan outlined in “7540 Dimensional Inspection” for (FRM-01379; Rev AA) to use the (b)(4) density from the first (b)(4) BEAR Implants per lot to accept lots which meet the density specification ((b)(4)) on the premise that the collagen slurry mixture in the (b)(4) manufacturing step would have met the homogeneity specification is not based on valid statistical rationale. For example, per your Vice President of Research and Development and Manufacturing, if a single implant fails the density acceptance criteria, it will still be released, so long as the (b)(4) density of the (b)(4) implants remain within specification. On the other hand, if the (b)(4) density of the (b)(4) implants fails, then density is calculated on every implant within the lot, and all samples that do not meet specification will be treated as a nonconformance and scrapped. However, the rationale for this sampling plan is not based on valid statistical rationale because (1) samples are not taken at random; (2) samples are not based on lot sizes which can be up to (b)(4) units; (3) individual samples may still fail to meet density specifications, even if the previous collagen slurry specification met the specification for homogeneity; and (4) single implants which do not meet density specifications have the potential to be released if the (b)(4) density specification is met. The practice of releasing product when an individual data point was outside of the specification also constitutes distribution of nonconforming product without valid justification. Your complaint and\u002For corrective and preventive action investigations have determined that the gelation process affects densities such that implants with low densities can cause rapid blood absorption and those with high densities can delay or hinder blood absorption, both of which can render the implant unusable due to disintegration or lack of proper hydration, the result of which is delayed surgery requiring use of a second implant (if available) or impaired (b)(4) per lines (b)(4) through (b)(4) of your hazard analysis (001-003-HZ; Rev. B; Effective: 7\u002F10\u002F23).\nWe reviewed your firm’s response and conclude that it is not adequate. Per the response to the process validation observation, which employed the same (b)(4) sampling plan strategy as that used during lot release of product, you provided no corrective actions on the basis that an (b)(4) sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an (b)(4) characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the (b)(4) density from the (b)(4) lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. Therefore, please provide a response as to how you plan to address the above deficiency.\n6. Failure to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and documented evaluation and selection of potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements, as required by 21 CFR 820.50(a)(1).\nSpecifically, you failed to implement:\na. Sections 4 and 18 of your “Supplier Quality Agreement” (Approved 1\u002F27\u002F22) which require you to approve protocols and reports for process, sterilization and inspection\u002Ftest validations performed by the contract manufacturer and “***provide copies of quality records upon request***,” respectively. For example, your contract manufacturer refused to provide unredacted supporting documents, such as the process routers, device history records, and process parameters used to manufacture the BEAR Implant device during the FDA inspection.\nb. Section 4.8 of your “Supplier Management” (SOP-0025; Rev. D; Effective: 12\u002F8\u002F23) which requires (b)(4) evaluation of major suppliers using the “Supplier Re-evaluation Form” (FRM-0025). For example, your contract manufacturer of the BEAR Implant device has not been evaluated since May 2023 despite being categorized as a major supplier.\nc. Section 4.1.1 of SOP-0025 which requires “***no products or services associated with the QMS are to be purchased from a supplier not on the Approved Supplier List***.” For example, your firm’s microbiology consultant who authored “Rationale for Eliminating (b)(4) for the Test of Sterility and Anaerobic Bioburden Monitoring” dated 7\u002F30\u002F23 was not on the Approved Supplier List or evaluated. You have been using this consultant since November 2021.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-007, your immediate correction is to complete the 2024 supplier re-evaluation form for the contract manufacturer and for the consultant and revise the quality agreement to allow alternative methods for reviewing all supporting documentation for process, sterilization, and inspection\u002Ftest validations such as onsite review, establishing a master file with the FDA, or having a 3rd party consultant review the documents. As a part of corrective actions, you plan to perform a gap analysis for the approved supplier list and revise SOP-0025 to allow alternative methods for review of supporting documents. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n7. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluations to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).\nSpecifically, you failed to implement section 4.3.6 of your “Customer Feedback” procedure (SOP-0027; Rev. B – C; Effective: 6\u002F27\u002F24 and 12\u002F8\u002F23) which requires you to categorize customer feedback as complaints, to be processed by the “Complaint Management” procedure (SOP-0019; Rev. C – D; Effective: 12\u002F8\u002F23 and 4\u002F26\u002F24), when they meet the definition of complaints as defined under section 3 of SOP-0027. For example, your customer feedback descriptions in 3 out of 6 reviewed customer feedback forms, which met the definition of complaints, were classified as “Observations” instead of “Complaints” and, therefore, did not include documented evaluations for medical device reporting (MDR) and investigations per sections 4.2 and 4.3 of SOP-0019, respectively, as evidenced below:\na. CF 2024-006 (6\u002F3\u002F24): BEAR Implant “***hydrating far too quickly (\u003C10 seconds) and becoming unable to properly implant***.”\nb. CF 2024-004 (4\u002F12\u002F24): BEAR Implant “***hydrated EXTREMELY slow. Took 20 cc and maybe 5 min. Much much much slower than average hydration. Could tell the implant was very dense when the surgeon slid Keith needle into it***.”\nc. CF 2023-007 (3\u002F7\u002F23): BEAR Implant “***it was too dense and seemed not to have a porous side. This happened with two of the implants***He is concerned about the variability between implants of the same lot, and does not like the difficulty he had hydrating it***.”\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-009, your immediate corrections are to process the above incidents as complaints and retrospectively review “observations” since 2021 to ensure that no other complaints were missed. As a part of corrective actions, you plan to provide training to ensure that future customer feedback is evaluated in accordance with SOP-0019 and update the training procedure (SOP-004) to control training in accordance with the risk inherent in the process. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n8. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, you failed to adequately implement section 4.2 of your firm's “Corrective and Preventive Action Procedure” (SOP-0014; Rev. C; Effective: 9\u002F8\u002F21) which requires completion of a Field Action Decision Form (FADF) and risk assessment if product in the field may be impacted. For example, the FADF for CAPA 2023-001, initiated on 1\u002F27\u002F23 in response to complaints regarding rapid blood absorption and disintegration of BEAR Implants from Lot # (b)(4), concluded that a field action was not required per the results of the Health Hazard Evaluation (HHE) Form (DCR 2019-005; Approved 2\u002F17\u002F23) which determined that the hazard of \"ACL is not fully healed\" ((b)(4)) was “low risk” when an occurrence rating of (b)(4) was applied. However, this conclusion conflicted with the original “Internal Memorandum***Risk Assessment” conducted per the “Risk Management Plan – BEAR Implant (Project: 001)” (DCR 2020-008; Rev. B; Effective: 8\u002F27\u002F20) on 1\u002F30\u002F23 which found that the risk for this same hazard (b)(4) was “Unacceptable” (“further risk reduction or additional risk-benefit is required”) when an occurrence rating of (b)(4) was applied. Applying this same occurrence level of (b)(4) to the HHE would have moved the risk level from “low” to “high” (“Field action is required”). Therefore, you failed to conduct an adequate risk assessment under this CAPA 2023-001 in that the discrepancy in occurrence ratings between the HHE and the “Internal Memorandum*** Risk Assessment” was not resolved prior to completion of the FADF.\nWe reviewed your firm’s response and conclude that it is not adequate. You stated that there are no BEAR implants that remain in commercial distribution. Under CAPA 2025-006, your immediate correction is to reopen CAPA 2023-001 for review and reiteration if needed. As a corrective action, you plan to revise SOP-0014 to require that FADFs, Health Hazard Assessments, and Risk Assessments are compared for correlation and completeness and that at least two reviewers are included for the assessments. However, no timelines were provided for these corrective actions. In addition, although you obtained Lot #(b)(4) from your sales personnel, no corrective actions were identified to document justification for not reporting a correction and\u002For removal of product from the field, including removals limited to sales personnel, to the FDA. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nMedical Device Reporting (MDR) Violation(s)\n9. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nSpecifically, during the inspection, your firm presented its MDR procedure titled “Medical Device Reporting,” SOP‐0023, Revision B, dated: 8‐Dec‐2023. For example, after reviewing the procedure, the following deficiencies were noted:\na. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\ni. The procedure SOP‐0023, Revision B, does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\nii. There are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” and “serious injury,” nor the definition of “reasonably suggests” found in 21 CFR 803.20(c)(1). The absence of these definitions may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a). Without adequate definitions, your procedure lacks executable instructions or the level of detail needed to ensure timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements.\nb. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\nc. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include the circumstances under which your firm must submit initial 30-day, supplement or follow-up and 5‐day reports and the requirements for such reports.\nd. The procedure SOP‐0023, Revision B, does not adequately describe how your firm will address documentation and record‐keeping requirements, as required by 21 CFR 803.17(b). Specifically, while Section 4.1.3 of the SOP references retaining data for reportable events, it lacks sufficient detail on how the deliberations and decision-making processes used to determine whether an event is reportable or not is to be documented, as required under 21 CFR 803.18(b)(1)(i).\nYour firm’s response dated May 13, 2025 did not address the noted procedural deficiencies as they were not listed on the FDA Form 483.\nOur inspection also revealed that your firm’s BEAR implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\n10. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint 2023‐011 reasonably suggests that the patient developed an infection at the site of BEAR implant after falling 4.5 weeks post-surgery. Although the information included for the complaint establishes that the device did not malfunction in that the ACL damage observed was the result of a re‐tear due to the fall, the occurrence of the infection in the area surrounding the implantation reasonably suggests that the device may have been a factor in the serious injury event that necessitated irrigation and antibiotic treatment to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on August 23, 2023; however, no corresponding MDR was received by the FDA.\nYour firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. However, the response indicated that your firm conducted a reportability evaluation in relation to Observation 9. Upon review, the response did not include any information regarding plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\n11. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Complaints 2022‐001, 2023‐004 and 2024‐001 reasonably suggests that your firm’s BEAR implant malfunctioned (i.e., improper hydration) while in use. The device is a long‐term implantable device. Generally, malfunctions are reportable if they involve a long-term implant and are likely to cause or contribute to death or serious injury, or the malfunction results in the failure of the device to perform its essential function, thereby compromising its therapeutic effectiveness which could cause or contribute to a death or serious injury. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63858 (Dec. 11, 1995), Comment 12, for more information. We believe an improperly hydrated BEAR implant could compromise its structural integrity and therapeutic function, leading to serious complications that might cause or contribute to a death or serious injury. Therefore, the referenced complaints represent MDR reportable events as defined in 21 CFR 803.3. Your firm became aware of information on September 1, 2022, for Complaint 2022‐001, on February 24, 2023, for Complaint 2023‐004, and on January 11, 2024, for Complaint 2024‐001. However, the FDA has not received an MDR for any of these referenced events.\nYour firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. The response noted that your firm conducted a reportability evaluation and will submit MDRs for Complaints 2022‐001 and 2024‐001. However, the response does not address Complaint 2023‐004. Additionally, your firm has not provided any information indicating plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 709827” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nRita Paparazzo\nVP of Quality, Regulatory, and Clinical Affairs\nrpaparazzo@miachortho.com","Miach Orthopaedics","miach-orthopaedics-709827-08192025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiach-orthopaedics-709827-08192025","2026-10-26T08:09:24.573281+00:00","Warning Letter","Issued","2025-08-26","709827","Medical Devices","Patrick McBrayer","2026-08-19T16:29:01.377+00:00","VIA Electronic Mail","2025-08-19",{"id":32,"raw":33,"subject":12,"body_html":37,"body_text":38,"firm_name":39,"letter_id":40,"created_at":41,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":46,"body_fetched_at":47,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":48,"medical_device_id":19,"response_letter_date":19},252,[34,35,36,11,12,13,13,13],"\u003Ctime datetime=\"2026-03-24T04:00:00Z\">03\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-24T05:00:00Z\">02\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fisotis-orthobiologics-inc-723370-02242026\">IsoTis OrthoBiologics, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Peter P. Nalbach\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager of Spine Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IsoTis OrthoBiologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2 Goodyear, Ste A,\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #723370\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 24, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Nalbach:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from October 6, 2025, through October 17, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures resorbable calcium salt bone void filler devices, branded under the Accell Family of products, to include the Accell Evo3c. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, your manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from your Director Quality Systems, dated November 7, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>Your firm failed to adequately take action to correct the cause of nonconformities in order to prevent recurrence. Your firm's corrective and preventative action procedure, Corrective and Preventive Actions CP-1001 Rev. J Effective: 8\u002F22\u002F2022, requires your firm to perform an investigation, determine the need for containment, and assess the risk associated with the issue.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination occurring during the demineralization process of bone tissue, due to the propeller blade contacting the bottom of the demineralization vessel. The issue was discovered by a manufacturing engineer and documented in emails dating back to 06\u002F22\u002F2023.\u003C\u002Fp>\u003Cp>As part of CAPA 157738, your firm conducted a risk assessment for the demineralization process. In your risk analysis document, PFMEA-011 Rev. 12, effective October 23, 2023, your firm identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a risk for particulate contamination. This risk was assigned a severity rating of Moderate and a probability of Improbable, resulting in an overall Acceptable risk rating. Despite discovering that the propeller blade was potentially shedding \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles during demineralization, your firm did not investigate whether this finding affected your risk probability rating. In CAPA 157738, your firm classified the risk as low without providing justification for this conclusion and determined that containment action was not required due to your determined low risk. Your firm's CAPA investigation and actions are inadequate because it did not assess the potential impact to finished devices, including distributed product.\u003C\u002Fp>\u003Cp>Additionally, your firm’s Verification of Effectiveness included reviewing 18 work orders to confirm that visual inspection of the propeller was performed. The verification of effectiveness does not demonstrate that visual inspection of the propeller is sufficient to identify potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate in your firm's demineralized bone matrix (DBM). Your firm did not verify if the corrective actions performed were sufficient to correct the potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination.\u003C\u002Fp>\u003Cp>Your firm closed CAPA 157738 on 12\u002F17\u002F2024 without evidence that \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination was no longer occurring during your demineralization process.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. While your firm’s response acknowledges procedural deficiencies and proposes process improvements, the CAPA defers critical product risk elements to separate CAPAs without clear indication that all deficiencies identified in CAPA-157738 have been adequately addressed. For example, in HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints determined to be relevant now that \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination has been identified as a potential contributing factor. However, none of the related CAPAs indicate whether an MDR assessment was performed for these complaints.\u003C\u002Fp>\u003Cp>Additionally, it is not clear why the scope of the CAPA retrospective review is from 01\u002F01\u002F2022 to present.\u003C\u002Fp>\u003Cp>2. Failure to revalidate a validated process when changes or process deviations occurred, as required by 21 CFR 820.75(c). For example:\u003C\u002Fp>\u003Cp>Your firm’s procedure, Validation Program QA-035 Effective: 6\u002F11\u002F21, requires revalidation for previously validated process parameters, component changes, and major design changes; however, your firm did not revalidate your demineralization press when a major design change was made.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding that during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating the potential shedding of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates. Two corrective actions were implemented:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm updated TL-0091 for the Demineralization Press in design change order (DCO), DCO 6306 Released: 5\u002F24\u002F24, which changed the equipment design by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm determined that qualification or validation is not required, though the DCO describes the change category as Major. Your firm answered No to the question: Is there a change in the manufacturing equipment while maintaining the existing process? on your Form CPF-0302-001 Decision Tree, although your firm changed the equipment design by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm’s Director of Quality Systems and Assurance told the investigator that they considered the demineralization press to be a tool and not equipment.\u003C\u002Fp>\u003Cp>Additionally, your firm determined that \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection was sufficient to identify potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants and required training of your demineralization team to \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspect the propellers, however your firm has not validated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection process for the propeller blades to demonstrate it is sufficient in identifying potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants in your firm’s demineralized bone matrix (DBM). In an email from your firm’s manufacturing engineer, they note that \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address production and process related deficiencies identified in Observation 2. Actions include validating the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection method with \u003Cstrong>(b)(4)\u003C\u002Fstrong> study, completing Installation Qualification for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> demineralization assemblies, and establishing preventative maintenance and calibration programs. However, while your firm validated the inspection method and qualified equipment, there is no objective evidence that:\u003C\u002Fp>\u003Cul>\u003Cli>An evaluation of the existing process validation was conducted to determine if the changes to the demineralization assemblies could impact the applicability of the existing Operational and Performance Qualifications.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination is no longer occurring in production and that the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\" clearance is sufficient to prevent all contact under all operating conditions\u003C\u002Fli>\u003Cli>Testing has been performed to confirm absence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles in DBM\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, the verification of effectiveness plan measures compliance to procedures and execution of preventative maintenance but does not include testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates in finished product.\u003C\u002Fp>\u003Cp>Additionally, it is not clear why the scope identified in CAPA-100520 for reviewing tooling changes is January 2022 to present, when the affected timeframe extends back to 2008.\u003C\u002Fp>\u003Cp>3. Failure to establish an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>Your firm’s procedure, CP-0305 Risk Management Rev. J1 Effective: 5\u002F27\u002F22, requires in Section 6.26.2 Perform Risk Reassessment (As Necessary), that if new or updated risk information is identified, it will be fed back into the risk management system and documented via update and approval of the appropriate risk management forms (such as the Hazard Analysis or FMEA).\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding, during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating potential shedding of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates. The CAPA identified the risk in PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II as \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Supplier error leading to particulate contamination resulting in transient inflammation, which defined a severity of Moderate and a probability occurrence of Improbable, and the Risk Acceptability as Acceptable.\u003C\u002Fp>\u003Cp>Your firm identified the propeller blade was potentially shedding \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates during the demineralization process; however, your firm did not update PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II to identify this new risk factor. \u003Cstrong>(b)(4)\u003C\u002Fstrong> only addresses potential contaminants from your supplier resulting in transient inflammation and does not address the risk of contaminants during your firm’s manufacturing processes. Your firm did not identify the risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants and the potential impact to patient harm. Your firm’s risk management files were not updated after identifying this new risk, including identifying the severity of patient harm, as required by your procedure.\u003C\u002Fp>\u003Cp>Additionally, your firm did not reevaluate the probability of occurrence for potential contaminants. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Supplier error leading to particulate contamination resulting in transient inflammation defines a probability occurrence of Improbable. Your firm did not update the occurrence probability after identifying the new risk of potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants.\u003C\u002Fp>\u003Cp>According to your firm’s Senior Manager, New Product Initiatives and Sustaining Engineering, since your firm implemented the demineralized process in 2008, \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates may have been present in your DBM, potentially impacting over \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address risk management deficiencies identified in Observation 3. Although your firm acknowledges that risk assessment associated with CAPA 157738 and related PFMEAs and Hazard Analysis (HA-\u003Cstrong>(b)(4)\u003C\u002Fstrong>) required revision and initiated procedural changes, your response is still inadequate. Your firm’s actions included:\u003C\u002Fp>\u003Cul>\u003Cli>Updated PMFEAs (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Updated Hazard Analysis HA-\u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Conducted a retrospective Health Hazard Evaluation (HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> concluded that no correction, removal, or recall recommended, as the risk level assessed as Low and Acceptable. Your firm acknowledges that \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination occurred from 2008-2024, with over \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices potentially affected, however no actual testing was performed to confirm the absence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in distributed product. The HHE is deficient in that:\u003C\u002Fp>\u003Cul>\u003Cli>Your firm reviewed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints and deemed \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinically relevant for your probability calculation. There was no clear indication on which were not deemed clinically relevant and why. Your firm concluded that \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints related to \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination without adequately documenting an investigation showing how they ruled out \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination as a contributing factor.\u003C\u002Fli>\u003Cli>Your firm’s Probability Assessment disregards potential inflammation or foreign body reaction due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles as typical post-surgical inflammation\u003C\u002Fli>\u003Cli>Severity Assessment deemed Moderate, which firm has defined in your firm’s procedure, Risk Management Rev. J1 Effective: 5\u002F27\u002F22 and identified in the Severity Ratings Table in HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> as a minor intervention (i.e. Medical intervention that may result in procedural delay, requiring removal and re-insertion of device resulting in additional patient discomfort or increased anesthesia requirements; Minor, transient, or self-limiting injury not requiring medical intervention; Cancellation of an elective medical procedure \u002F surgery). While complaint data included in HHE includes revision surgery, hospitalization, IV antibiotics, osteolysis consistent with a higher severity rating as noted in your procedure.\u003C\u002Fli>\u003Cli>Biocompatibility has not been adequately evaluated. Your firm states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used in permanently implanted devices (stents, pledgets, endoprostheses), therefore, \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure is not expected to cause adverse effects. However, the cited devices use intact \u003Cstrong>(b)(4)\u003C\u002Fstrong> structures, not particulate contamination. Your firm provides no data demonstrating that they have:\u003Cbr>o Characterized potential particle generation during normal use and wear.\u003Cbr>o Conducted biocompatibility testing per ISO 10993 standards if particle release is expected.\u003Cbr>o Assessed the clinical significance of any particle elution through risk analysis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on October 6, 2025 through October 17, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS Case 723370\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden&nbsp;&nbsp;\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPeter P. Nalbach\n\nRecipient Title\n\nVice President and General Manager of Spine Operations\n\nIsoTis OrthoBiologics, Inc.\n\n2 Goodyear, Ste A,\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #723370\nFebruary 24, 2026\nDear Mr. Nalbach:\nDuring an inspection of your firm located in Irvine, CA from October 6, 2025, through October 17, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures resorbable calcium salt bone void filler devices, branded under the Accell Family of products, to include the Accell Evo3c. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, your manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from your Director Quality Systems, dated November 7, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\nYour firm failed to adequately take action to correct the cause of nonconformities in order to prevent recurrence. Your firm's corrective and preventative action procedure, Corrective and Preventive Actions CP-1001 Rev. J Effective: 8\u002F22\u002F2022, requires your firm to perform an investigation, determine the need for containment, and assess the risk associated with the issue.\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address potential (b)(4) particulate contamination occurring during the demineralization process of bone tissue, due to the propeller blade contacting the bottom of the demineralization vessel. The issue was discovered by a manufacturing engineer and documented in emails dating back to 06\u002F22\u002F2023.\nAs part of CAPA 157738, your firm conducted a risk assessment for the demineralization process. In your risk analysis document, PFMEA-011 Rev. 12, effective October 23, 2023, your firm identified (b)(4) as a risk for particulate contamination. This risk was assigned a severity rating of Moderate and a probability of Improbable, resulting in an overall Acceptable risk rating. Despite discovering that the propeller blade was potentially shedding (b)(4) particles during demineralization, your firm did not investigate whether this finding affected your risk probability rating. In CAPA 157738, your firm classified the risk as low without providing justification for this conclusion and determined that containment action was not required due to your determined low risk. Your firm's CAPA investigation and actions are inadequate because it did not assess the potential impact to finished devices, including distributed product.\nAdditionally, your firm’s Verification of Effectiveness included reviewing 18 work orders to confirm that visual inspection of the propeller was performed. The verification of effectiveness does not demonstrate that visual inspection of the propeller is sufficient to identify potential (b)(4) particulate in your firm's demineralized bone matrix (DBM). Your firm did not verify if the corrective actions performed were sufficient to correct the potential (b)(4) particulate contamination.\nYour firm closed CAPA 157738 on 12\u002F17\u002F2024 without evidence that (b)(4) particulate contamination was no longer occurring during your demineralization process.\nWe reviewed your firm’s response and conclude that it is not adequate. While your firm’s response acknowledges procedural deficiencies and proposes process improvements, the CAPA defers critical product risk elements to separate CAPAs without clear indication that all deficiencies identified in CAPA-157738 have been adequately addressed. For example, in HHE-(b)(4), your firm identified (b)(4) complaints determined to be relevant now that (b)(4) contamination has been identified as a potential contributing factor. However, none of the related CAPAs indicate whether an MDR assessment was performed for these complaints.\nAdditionally, it is not clear why the scope of the CAPA retrospective review is from 01\u002F01\u002F2022 to present.\n2. Failure to revalidate a validated process when changes or process deviations occurred, as required by 21 CFR 820.75(c). For example:\nYour firm’s procedure, Validation Program QA-035 Effective: 6\u002F11\u002F21, requires revalidation for previously validated process parameters, component changes, and major design changes; however, your firm did not revalidate your demineralization press when a major design change was made.\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding that during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating the potential shedding of (b)(4) particulates. Two corrective actions were implemented:\n(b)(4)\n(b)(4)\nYour firm updated TL-0091 for the Demineralization Press in design change order (DCO), DCO 6306 Released: 5\u002F24\u002F24, which changed the equipment design by (b)(4). Your firm determined that qualification or validation is not required, though the DCO describes the change category as Major. Your firm answered No to the question: Is there a change in the manufacturing equipment while maintaining the existing process? on your Form CPF-0302-001 Decision Tree, although your firm changed the equipment design by (b)(4). Your firm’s Director of Quality Systems and Assurance told the investigator that they considered the demineralization press to be a tool and not equipment.\nAdditionally, your firm determined that (b)(4) inspection was sufficient to identify potential (b)(4) contaminants and required training of your demineralization team to (b)(4) inspect the propellers, however your firm has not validated the (b)(4) inspection process for the propeller blades to demonstrate it is sufficient in identifying potential (b)(4) contaminants in your firm’s demineralized bone matrix (DBM). In an email from your firm’s manufacturing engineer, they note that (b)(4) particulates are (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address production and process related deficiencies identified in Observation 2. Actions include validating the (b)(4) inspection method with (b)(4) study, completing Installation Qualification for all (b)(4) demineralization assemblies, and establishing preventative maintenance and calibration programs. However, while your firm validated the inspection method and qualified equipment, there is no objective evidence that:\nAn evaluation of the existing process validation was conducted to determine if the changes to the demineralization assemblies could impact the applicability of the existing Operational and Performance Qualifications.\n(b)(4) particulate contamination is no longer occurring in production and that the (b)(4)\" clearance is sufficient to prevent all contact under all operating conditions\nTesting has been performed to confirm absence of (b)(4) particles in DBM\nFurthermore, the verification of effectiveness plan measures compliance to procedures and execution of preventative maintenance but does not include testing for (b)(4) particulates in finished product.\nAdditionally, it is not clear why the scope identified in CAPA-100520 for reviewing tooling changes is January 2022 to present, when the affected timeframe extends back to 2008.\n3. Failure to establish an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\nYour firm’s procedure, CP-0305 Risk Management Rev. J1 Effective: 5\u002F27\u002F22, requires in Section 6.26.2 Perform Risk Reassessment (As Necessary), that if new or updated risk information is identified, it will be fed back into the risk management system and documented via update and approval of the appropriate risk management forms (such as the Hazard Analysis or FMEA).\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding, during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating potential shedding of (b)(4) particulates. The CAPA identified the risk in PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II as (b)(4) for Supplier error leading to particulate contamination resulting in transient inflammation, which defined a severity of Moderate and a probability occurrence of Improbable, and the Risk Acceptability as Acceptable.\nYour firm identified the propeller blade was potentially shedding (b)(4) particulates during the demineralization process; however, your firm did not update PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II to identify this new risk factor. (b)(4) only addresses potential contaminants from your supplier resulting in transient inflammation and does not address the risk of contaminants during your firm’s manufacturing processes. Your firm did not identify the risk of (b)(4) contaminants and the potential impact to patient harm. Your firm’s risk management files were not updated after identifying this new risk, including identifying the severity of patient harm, as required by your procedure.\nAdditionally, your firm did not reevaluate the probability of occurrence for potential contaminants. (b)(4) Supplier error leading to particulate contamination resulting in transient inflammation defines a probability occurrence of Improbable. Your firm did not update the occurrence probability after identifying the new risk of potential (b)(4) contaminants.\nAccording to your firm’s Senior Manager, New Product Initiatives and Sustaining Engineering, since your firm implemented the demineralized process in 2008, (b)(4) particulates may have been present in your DBM, potentially impacting over (b)(4) devices.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address risk management deficiencies identified in Observation 3. Although your firm acknowledges that risk assessment associated with CAPA 157738 and related PFMEAs and Hazard Analysis (HA-(b)(4)) required revision and initiated procedural changes, your response is still inadequate. Your firm’s actions included:\nUpdated PMFEAs ((b)(4)) to include (b)(4)\nUpdated Hazard Analysis HA-(b)(4) to (b)(4)\nConducted a retrospective Health Hazard Evaluation (HHE-(b)(4))\nHHE-(b)(4) concluded that no correction, removal, or recall recommended, as the risk level assessed as Low and Acceptable. Your firm acknowledges that (b)(4) contamination occurred from 2008-2024, with over (b)(4) devices potentially affected, however no actual testing was performed to confirm the absence of (b)(4) in distributed product. The HHE is deficient in that:\nYour firm reviewed (b)(4) complaints and deemed (b)(4) clinically relevant for your probability calculation. There was no clear indication on which were not deemed clinically relevant and why. Your firm concluded that (b)(4) complaints related to (b)(4) contamination without adequately documenting an investigation showing how they ruled out (b)(4) contamination as a contributing factor.\nYour firm’s Probability Assessment disregards potential inflammation or foreign body reaction due to (b)(4) particles as typical post-surgical inflammation\nSeverity Assessment deemed Moderate, which firm has defined in your firm’s procedure, Risk Management Rev. J1 Effective: 5\u002F27\u002F22 and identified in the Severity Ratings Table in HHE-(b)(4) as a minor intervention (i.e. Medical intervention that may result in procedural delay, requiring removal and re-insertion of device resulting in additional patient discomfort or increased anesthesia requirements; Minor, transient, or self-limiting injury not requiring medical intervention; Cancellation of an elective medical procedure \u002F surgery). While complaint data included in HHE includes revision surgery, hospitalization, IV antibiotics, osteolysis consistent with a higher severity rating as noted in your procedure.\nBiocompatibility has not been adequately evaluated. Your firm states that (b)(4) is used in permanently implanted devices (stents, pledgets, endoprostheses), therefore, (b)(4) exposure is not expected to cause adverse effects. However, the cited devices use intact (b)(4) structures, not particulate contamination. Your firm provides no data demonstrating that they have:\no Characterized potential particle generation during normal use and wear.\no Conducted biocompatibility testing per ISO 10993 standards if particle release is expected.\no Assessed the clinical significance of any particle elution through risk analysis.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on October 6, 2025 through October 17, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723370” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","IsoTis OrthoBiologics, Inc.","isotis-orthobiologics-inc-723370-02242026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fisotis-orthobiologics-inc-723370-02242026","2026-10-26T08:09:01.474861+00:00","2026-03-24","723370","Peter P. Nalbach","2026-08-19T04:50:13.031+00:00","2026-02-24",{"id":50,"raw":51,"subject":12,"body_html":56,"body_text":57,"firm_name":58,"letter_id":59,"created_at":41,"fei_number":19,"letter_url":60,"updated_at":61,"action_type":22,"case_status":23,"posted_date":62,"marcs_cms_no":63,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":64,"body_fetched_at":65,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":66,"medical_device_id":19,"response_letter_date":19},279,[52,53,54,11,55,13,13,13],"\u003Ctime datetime=\"2026-03-10T04:00:00Z\">03\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-19T05:00:00Z\">12\u002F19\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexactech-inc-dba-advita-ortho-720250-12192025\">Exactech, Inc. dba Advita Ortho \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Aurelio Sahagun\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Exactech, Inc. dba Advita Ortho \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2320 Nw 66th Ct\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gainesville\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32653-1630\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:aurelio.sahagun@advita.com\"> aurelio.sahagun@advita.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 720250\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 19, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Sahagun:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Sarasota, Florida from July 15, 2025, through July 25, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Equinoxe Reverse Shoulder Compression Screw along with other accessories of the Equinoxe Reverse Shoulder System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Mathew Collins, Vice President of Quality dated August 15, 2025, along with response updates concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a). For example, your firm failed to adequately establish production and process control procedures to ensure that devices conform to specifications.\u003C\u002Fp>\u003Cp>A. Your firm failed to define \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications and testing for polymer powder fabricated into UHMWPE molded products to ensure device components meet specified requirements. The document titled, “Ultra-High Molecular Weight Polyethylene (UHMWPE) ETS-0121 Rev. J”, released 02\u002F23\u002F2022 and “Compression Molded UHMW Polyethylene ETS-0122 Rev. L”, released 06\u002F27\u002F2022 call out \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Implants for surgery – \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively. Your firm has no records of \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing for lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> products to verify compliance with required \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Certificate of Conformance values for lots are based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> qualification testing of polymer powder fabricated into \u003Cstrong>(b)(4)\u003C\u002Fstrong> products rather than actual manufactured products.\u003C\u002Fp>\u003Cp>1. Investigators noted that \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurement value of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, documented on the Certificate of Conformance for part number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not based on testing conducted on molded\u002Ffabricated parts. Rather the nominal values documented on this Certificate of Conformance, are based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw powder, identified with lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initially received on or around December 2021. Your firm declares compliance to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Implants for surgery – \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cstrong>(b)(4)\u003C\u002Fstrong> which notes the physical property requirements of \u003Cstrong>(b)(4)\u003C\u002Fstrong> molded products and states in part, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The qualification testing is documented on Technical Memo TM-2021-1578, with approval dates 01\u002F18-19\u002F2022, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> test result were documented as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. Production and process procedures do not clearly define process controls necessary to ensure conformance to specifications. Your firm failed to adequately document instructions, standard operating procedures, and methods that define and control the manner of production.\u003C\u002Fp>\u003Cp>1. The work instructions do not define and control the manner of production, including in-process inspection of a critical specification and use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tool. The Equinoxe Reverse Shoulder Torque Screw devices critical specification for break-point dimension inspection (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) relies on \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection with significant operator variability. However, Work Instruction titled, Complete and Document Inspection of Machined Product at Sarasota- Machining 701-105-945 Rev. D, also does not clearly or explicitly outline the production and processing controls or provide step-by-step directions for the required, in-process inspections of the Equinoxe Torque Screw device, including specific instructions, equipment needed, process or product parameters or specifications, or inspection requirements.\u003C\u002Fp>\u003Cp>i. FDA investigators noted that an operator was performing this inspection step that required \u003Cstrong>(b)(4)\u003C\u002Fstrong> to undergo and pass this in-process inspection step out of a sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. At the time the investigators observed this in-process inspection being performed, two of the required \u003Cstrong>(b)(4)\u003C\u002Fstrong> had undergone and passed this inspection step. The investigators noted that a sample unit, identified the torque screw as passing and meeting the required specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from point A to B. However, investigators reviewed the measurements and noted that the unit did not pass this \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection test as the unit did not appear to fall completely within the specified \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tool image that reflect tolerance limits. Three nonconforming devices were later scrapped as noted on the scrap log and Production Events log.\u003C\u002Fp>\u003Cp>2. Manufacturing procedures do not adequately define process controls, in-process inspections, or equipment specifications. Work Instruction titled, Machine Equinoxe Reverse Shoulder Liner at Sarasota-Machining 701-105-896 Rev. C, released 04\u002F15\u002F2024, does not clearly or explicitly outline the production or processing controls or provide step-by-step directions for the manufacture of the Equinoxe Shoulder Liner device including specific instructions, equipment needed, process or product parameters or specifications, or inspection requirements. Additionally, your firm’s Work Instruction titled, Complete and Document Inspection of Machined Product at Sarasota- Machining 701-105-945 Rev. D, also does not clearly or explicitly outline the production and processing controls or provide step-by-step directions for the required, in-process inspections of the Equinoxe Shoulder Liner device, including specific instructions, equipment needed, process or product parameters or specifications, or inspection requirements. Neither of these Work Instructions document specific instruction on how to perform this inspection test, such as use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tool, and operator \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not addressed. Furthermore, no Operational Qualification was documented for \u003Cstrong>(b)(4)\u003C\u002Fstrong> machining processes, of the Equinoxe Polyethylene Shoulder Liner device and devices do not undergo \u003Cstrong>(b)(4)\u003C\u002Fstrong> in-process or final testing.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. The responses note that the root causes and contributing factors of the process control deficiencies include inconsistent enforcement of validation requirements, gaps in operator training on comparator-based inspections, and absence of formal inspection method qualification. In addition, the responses note that these deficiencies have systemic implications across your firm’s manufacturing operations and as well design transfer activities. Your firm’s responses describe corrections that include a manufacturing and process hold, \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection of existing inventory during process hold and a Field Action for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Humeral Shoulder Liners. Your responses also describe corrective and preventative actions under CAPA 2025-30 that include: validation remediation for relevant manufacturing processes across Sarasota and Gainesville; SOP and work instruction redesign and training; inspection method qualification and retention of coordinate measuring machine reports; develop layered process audit work instructions and integration into QMS trending; SOP update for initial out of specification handing; and design transfer and process validation readiness. Your firm’s responses do not describe, and list remediation activities or products associated to legacy design transfer issues across manufacturing operations at your Sarasota and Gainesville facilities. The activities under CAPA 2025-30 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\u003C\u002Fp>\u003Cp>2) Failure to adequately establish and maintain procedures for corrective and preventative action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>A. The procedure for Corrective and Preventive Actions Procedure, 701-103-137, Rev. AB, dated 6\u002F11\u002F2025 does not identify production events as nonconformities or quality data. A Production Event (PE) is defined as an event generated in \u003Cstrong>(b)(4)\u003C\u002Fstrong> utilized for processing electronic device history records, due to a deviation from pre-established product or process specifications. Production Events (\u003Cstrong>(b)(4)\u003C\u002Fstrong> documented events) are not analyzed as quality data sources or escalated to CAPAs where appropriate. Investigators noted that from 07\u002F01\u002F2023 to 7\u002F25\u002F2025 there was incomplete documentation maintained or available to demonstrate which Production Event entries were documented and managed as nonconformances. Additionally, no documentation was maintained or available to demonstrate that any Production Events were further assessed or analyzed as quality data sources.\u003C\u002Fp>\u003Cp>B. CAPAs 2023-005 and 2025-005 addressing environmental control specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong> storage were verified as effective and closed, yet environmental monitoring data from March 2024 to current showed your firm continued to exceed allowable temperature and humidity limits. Temperature specifications were changed from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in June 2025 after historical data showed consistent excursions. The pFMEA for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Molding Process, FMEA-000445, Rev A, dated 8\u002F1\u002F2024, discusses product and process impact with high temperatures and humidity, and the potential failures related to air conditioning (HVAC). Specifically, the effect of high moisture in \u003Cstrong>(b)(4)\u003C\u002Fstrong> may impact the material strength.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s responses note corrective actions under CAPA 2025-31 that include: CAPA procedural updates for verification of effectiveness; updates to Quality System’s governance and Management Review process adding additional sources of quality data (Production Events, Work in Process Scrap , environmental monitoring data, etc.); updates to software validation to include evaluation for the identification of critical to quality attributes for continuous monitoring; updates to Document Control related to the QMS process change and the determination of quality data outputs for continuous monitoring; and CAPA remediation efforts for verification of effectiveness. Your responses do not describe any retrospective review necessary to assess whether quality data such as Production Events, Work in Process Scrap, etc. or other critical to quality data attributes represent nonconformances or other quality issues that may require the initiation of a CAPA. The activities under CAPA 2025-31 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\u003C\u002Fp>\u003Cp>3) Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example, your firm failed to identify, document, evaluate nonconforming product including the need for investigation and notification of the persons or organizations responsible.&nbsp;\u003C\u002Fp>\u003Cp>A. There was no written procedure for handling “Production Events (PE)” identified during manufacturing. The Nonconforming Product Handling Procedure, 701-103-013 Rev. AK, dated 9\u002F13\u002F2024, does not include a process to elevate Production Events to a nonconformance, despite the potential for rework may occur. Production Event entries included those for multiple inspection failures found at various stages in the manufacturing process (in-process inspection and QC inspection). For example:\u003C\u002Fp>\u003Cp>1. Failure of product’s dimensional specifications (\u003Cstrong>(b)(4)\u003C\u002Fstrong> failure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> failure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> failure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> radius) that may correlate with high scrap rates for dimensional defects.\u003Cbr>2. Surface quality defects that include those for molding contamination: inclusions on articulating surface and mold marks.\u003Cbr>3. Machining process issues from setup and tooling that may create recurring dimensional problems (undersize stems on “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, undersized pin head, undersize due to a fixture issue, damaged threads, smooth and inconsistent threads, burrs in threads).\u003Cbr>4. Packaging issues that include wrinkles on seal, crease in seal, cuts in bag, score mark, seal integrity, loss in vacuum, nonuniform seal, loose fibers and black particles, hair, black particles embedded in bag.\u003C\u002Fp>\u003Cp>B. The WIP Scrap Events Collection procedure does not define threshold levels for when internal WIP scrap should be documented as nonconformances. While supplier receiving inspection has defined thresholds (\u003Cstrong>(b)(4)\u003C\u002Fstrong> defect rate), no similar thresholds exist for internal operations. Scrap log includes entries for nonconforming product associated with manufacturing process control deficiencies which include:\u003C\u002Fp>\u003Cp>1. Machining setup issues where numerous entries are labeled as set up, \"setup part,\" \"dial in\" and tooling\u002Ffixture issues labeled as \"tool broke,\" “bad mold tool”, \"worn tool,\" \"loose tool” and “wrong offset” resulting in scrap from dimensional and product quality problems (button height, overall thickness, overall length, thread noting dings and dents).\u003C\u002Fp>\u003Cp>2. Molding process issues resulting in scrap from:\u003Cbr>i. Equipment power issues labeled as “power outage”, “power failure”, “press failure”, “power turned off”;\u003Cbr>ii. Hydraulic issues (hydraulic Hit\u002Floss, pressure drop);\u003Cbr>iii. Heating and cooling failure (pumps not turned on);\u003Cbr>iv. Manufacturing process control issues (“wrong recipes”, “tool not set up”, “missfil”, “not properly blowing out”) resulting in scrap from “flash leakage”, “inclusions on surface” and “under\u002Fover” weight product\u003C\u002Fp>\u003Cp>3. Product finishing issues from “over polishing”, “over blasting” and “thread chip wrap” resulting in nonconforming product dispositioned as scrap.\u003C\u002Fp>\u003Cp>4. Operator training issues as “operator error” entries for the machining, molding and finishing manufacturing processes resulting in dimensional and cosmetic nonconforming product dispositioned as scrap.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s responses note that corrective actions under CAPA 2025-31 that included: the coordination of the nonconformance program with the Production Events (PE) and work in process (WIP), and training development. Your firm’s retrospective review of WIP and PE does not include the rationale for timeframes selected. For example, you identified July 2024 through August 2025 for retrospective review; however, FDA investigators reviewed WIP and PE data from 7\u002F01\u002F2023 through 7\u002F25\u002F2025. In addition, we disagree with your investigation that raw data and pivot tables for Production Events and WIP Scrap entries revealed that the vast majority (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of Production Events were benign in nature, and resolved via appropriate mechanisms (e.g. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> fix, and approved reworks). Additionally, it is not clear from production event logs collected during the inspection how the in process and quality control inspection failures were handled.\u003C\u002Fp>\u003Cp>Your firm notes that although there were gaps in the inconsistent classification and escalation of quality events, that the nonconformances do not indicate a risk to product. FDA disagrees with this assessment in that this does represent a potential risk to distributed product since the FDA inspection and your firm’s investigation identified gaps with QC work instructions and training. Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> in-process inspection using manual \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked formal work instruction to define the method, criteria, or documentation required. This created variability in execution and no documented evidence of consistency or repeatability. Your firm’s CAPA Review Board (CRB) identified this as a systemic breach of regulatory and QMS requirements; however, the assessment noted that it did not require a reportable field action. FDA remains concerned with the potential distribution of nonconforming product.\u003C\u002Fp>\u003Cp>The activities under CAPA 2025-31 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\u003C\u002Fp>\u003Cp>4) Failure to adequately establish and maintain procedures to ensure that environmental conditions do not adversely affect product quality, as required by 21 CFR 820.70(c). For example, your firm failed to adequately establish procedures to ensure your environmental controls are being maintained as specified and that your environmental control systems are adequate and functional.\u003C\u002Fp>\u003Cp>A. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Raw Material Storage, QWI-000185, Rev A, dated 4\u002F30\u002F2024 and the current procedure, Rev B, dated 6\u002F10\u002F2025 were not followed for backup environmental monitoring when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system fails in the Sarasota Molding Facility. \u003Cstrong>(b)(4)\u003C\u002Fstrong> system graphs from March 2024 to July 2025 of both temperatures and relative humidity levels were commonly and routinely recorded to be outside of the specified, nominal limit levels.\u003C\u002Fp>\u003Cp>B. A Deviation\u002FChange Request, dated 05\u002F27\u002F2025, was “Due to a faulty environmental monitoring sensor (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) located in the controlled environment fill room, the sensor will be unplugged, and environmental monitoring will occur using a calibrated data logger for both temperature and humidity”. Only one of \u003Cstrong>(b)(4)\u003C\u002Fstrong> poly fill rooms is monitored by the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, with assumption that \u003Cstrong>(b)(4)\u003C\u002Fstrong> rooms maintain same conditions despite physical wall separation.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your responses note that corrective and preventative actions under CAPA 2025-033 included the environmental monitoring system enhancements; procedural revision to environmental monitoring excursion; training; updates to risk documents; new procedure to be used to document the facility modification; and defining environmental conditions of \u003Cstrong>(b)(4)\u003C\u002Fstrong> resin and molded components. The activities under along CAPA 2025-033 with the verification of effectiveness criteria, are in progress and extend through March 2026\u003C\u002Fp>\u003Cp>5) Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example, your firm failed to follow the procedures for Supplier Quality Management, 701-103-077, Rev AH, dated 10\u002F31\u002F2023. The FDA investigators noted that \u003Cstrong>(b)(4)\u003C\u002Fstrong>., the sole supplier of critical \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder, has not received a required on-site audit per Supplier Quality Management Procedure Section 5, Step F, Item 2.C. The last supplier evaluation was conducted in September 2020, with no reevaluation when current procedures were implemented in October 2023. Additionally, there is no signed quality agreement as required per the procedure Section V, Step C, item 4.\u003C\u002Fp>\u003Cp>Your firm’s pFMEAs for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> molded products document considers the raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder, a critical component of the processing and quality of the finished devices. In the Process FMEA Process Failure Mode and Effects Analysis \u003Cstrong>(b)(4)\u003C\u002Fstrong> Compression Molding Process, FMEA-000445 Rev. A, DCRTC-00194, dated 8\u002F1\u002F2024 notes that if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not properly received from the supplier and in conformance with the specifications, this could potentially lead to product impact with quality failures, incorrect traceability, higher product scrap or degraded mechanical characteristics.\u003C\u002Fp>\u003Cp>The FDA inspection noted that there were no records to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder supplier, has or is maintaining environmental controls and storage conditions of the supplied \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder component. The current lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder in use by your firm, lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was first qualified in 2021, and all \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder received since then, have been identified with the same lot identification. Documentation demonstrates the initial qualification of lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> in 2021; however, your firm has received approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipments of the same lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, since 2021 to 7\u002F25\u002F2025.\u003C\u002Fp>\u003Cp>The adequacy of your responses cannot be determined at this time. Your responses note the following activities being handled under CAPA2025-034: Supplier Quality Management SOP revision; the reevaluation of approved suppliers; the integration of supplier checks into design transfer activities; revise On-Site Audits and initiate Quality Agreements and On-Site Audits; and initiate Quality Agreements of \u003Cstrong>(b)(4)\u003C\u002Fstrong> powder. Many of the activities under CAPA2025-034 along with the verification of effectiveness criteria, are in progress and extend through June 2026. Therefore, we cannot determine the adequacy at this time.\u003C\u002Fp>\u003Cp>6) Failure to adequately establish procedures for identifying training needs and ensuring that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b). For example, your firm failed to capture the training of employees as described in the Competency and Training Procedure, 701-103-087, Rev. AB, dated 7\u002F9\u002F2024. FDA inspection noted that:\u003C\u002Fp>\u003Cp>A. \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees working in manufacturing did not have required QC inspection tools documented in their training records, not meeting the requirement that employees perform all necessary training prior to task execution without oversight.\u003C\u002Fp>\u003Cp>B. The procedure states that all retraining shall be documented and recorded as part of the employee’s training record. In the review of 11 nonconformance reports, 7 nonconformance reports identified operator error as the root cause. Retraining was not identified as an action item in 6 of 7 of the reports reviewed.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your responses note the following activities being handled under CAPA 2025-035 include implementation of Task-Level Training Controls; development of work instructions and inspection tools; documented on the job training; the revision of Nonconforming Product Handling Procedure to enforce training; and revision of competency and training procedure. Your firm’s response does not describe any necessary training as part of the design transfer activities associated to a new manufacturing or inspection process. The activities under CAPA 2025-035 along with the verification of effectiveness criteria, are in progress and extend through April 2026.\u003C\u002Fp>\u003Cp>7) Failure to adequately establish procedures for acceptance activities, as required by 21 CFR 820.80(a). For example:\u003C\u002Fp>\u003Cp>A. Your firm failed to identify the correct work instructions that applies to manufacturing personnel when using \u003Cstrong>(b)(4)\u003C\u002Fstrong> to produce products for the Truliant Knee 02-029-190-4300 Short Headed Pin For Syringe Pin Puller, Alteon Hip 180-165-20 Alteon 6.5MM Screw, 20MM, and the Equinoxe Shoulder Torque Defining Screws. The work instructions listed did not call out for manufacturing personnel to use the Manufacturing of Product in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Work Instruction, 701-105-1121, Rev D, effective date 2\u002F28\u002F2024. The work instructions are:\u003C\u002Fp>\u003Cp>1. Machining of Holding Pins at Sarasota- Machining Work Instruction 701-105-929, Rev. H, effective date 7\u002F15\u002F2025\u003Cbr>2. Machining of 6.5mm Alteon Cancellous Bone Screw at Sarasota-Machining and Finishing Work Instruction, 701-105-964, Rev. C, effective date 6\u002F22\u002F2021\u003Cbr>3. Manufacturing of Torque Defining Screws at Sarasota-Machining and Finishing Work Instruction, 701-105-1071, Rev B, effective date 11\u002F05\u002F2021\u003C\u002Fp>\u003Cp>B. Your firm failed to establish procedures or work instructions for two critical QC inspection tools used for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection process for the Equinoxe torque defining screw devices and for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection process for the Equinoxe shoulder liner device.\u003C\u002Fp>\u003Cp>The adequacy of your responses cannot be determined at this time. Your responses note that the following activities are being handled under CAPA 2025-036: updates on work instructions that support \u003Cstrong>(b)(4)\u003C\u002Fstrong>-controlled tasks and inspection operations; develop inspection tools and work instruction in conjunction with CAPA 2025-35; and work instruction impact review across similar product. The activities under CAPA 2025-036 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 720250” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.padilla@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Christine Thomas, Chief Quality, Clinical and Regulatory Officer, christine.thomas@advita.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAurelio Sahagun\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nExactech, Inc. dba Advita Ortho\n\n2320 Nw 66th Ct\n\nGainesville, FL 32653-1630\n\nUnited States\n\naurelio.sahagun@advita.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 720250\nDecember 19, 2025\nDear Mr. Sahagun:\nDuring an inspection of your firm located in Sarasota, Florida from July 15, 2025, through July 25, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Equinoxe Reverse Shoulder Compression Screw along with other accessories of the Equinoxe Reverse Shoulder System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Mathew Collins, Vice President of Quality dated August 15, 2025, along with response updates concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1) Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a). For example, your firm failed to adequately establish production and process control procedures to ensure that devices conform to specifications.\nA. Your firm failed to define (b)(4) specifications and testing for polymer powder fabricated into UHMWPE molded products to ensure device components meet specified requirements. The document titled, “Ultra-High Molecular Weight Polyethylene (UHMWPE) ETS-0121 Rev. J”, released 02\u002F23\u002F2022 and “Compression Molded UHMW Polyethylene ETS-0122 Rev. L”, released 06\u002F27\u002F2022 call out (b)(4) and (b)(4) (Implants for surgery – (b)(4) – (b)(4) respectively. Your firm has no records of (b)(4) testing for lots of (b)(4) products to verify compliance with required (b)(4) specifications of (b)(4). The Certificate of Conformance values for lots are based on (b)(4) qualification testing of polymer powder fabricated into (b)(4) products rather than actual manufactured products.\n1. Investigators noted that (b)(4) measurement value of (b)(4), documented on the Certificate of Conformance for part number (b)(4), is not based on testing conducted on molded\u002Ffabricated parts. Rather the nominal values documented on this Certificate of Conformance, are based on (b)(4) testing performed on the (b)(4) shipment of (b)(4) raw powder, identified with lot number (b)(4), initially received on or around December 2021. Your firm declares compliance to (b)(4) Implants for surgery – (b)(4) – (b)(4) which notes the physical property requirements of (b)(4) molded products and states in part, “(b)(4).” The qualification testing is documented on Technical Memo TM-2021-1578, with approval dates 01\u002F18-19\u002F2022, and the (b)(4) test result were documented as (b)(4).\nB. Production and process procedures do not clearly define process controls necessary to ensure conformance to specifications. Your firm failed to adequately document instructions, standard operating procedures, and methods that define and control the manner of production.\n1. The work instructions do not define and control the manner of production, including in-process inspection of a critical specification and use of the (b)(4) tool. The Equinoxe Reverse Shoulder Torque Screw devices critical specification for break-point dimension inspection ((b)(4)) relies on (b)(4) inspection with significant operator variability. However, Work Instruction titled, Complete and Document Inspection of Machined Product at Sarasota- Machining 701-105-945 Rev. D, also does not clearly or explicitly outline the production and processing controls or provide step-by-step directions for the required, in-process inspections of the Equinoxe Torque Screw device, including specific instructions, equipment needed, process or product parameters or specifications, or inspection requirements.\ni. FDA investigators noted that an operator was performing this inspection step that required (b)(4) to undergo and pass this in-process inspection step out of a sample size of (b)(4). At the time the investigators observed this in-process inspection being performed, two of the required (b)(4) had undergone and passed this inspection step. The investigators noted that a sample unit, identified the torque screw as passing and meeting the required specification of (b)(4), from point A to B. However, investigators reviewed the measurements and noted that the unit did not pass this (b)(4) inspection test as the unit did not appear to fall completely within the specified (b)(4) lines of the (b)(4) tool image that reflect tolerance limits. Three nonconforming devices were later scrapped as noted on the scrap log and Production Events log.\n2. Manufacturing procedures do not adequately define process controls, in-process inspections, or equipment specifications. Work Instruction titled, Machine Equinoxe Reverse Shoulder Liner at Sarasota-Machining 701-105-896 Rev. C, released 04\u002F15\u002F2024, does not clearly or explicitly outline the production or processing controls or provide step-by-step directions for the manufacture of the Equinoxe Shoulder Liner device including specific instructions, equipment needed, process or product parameters or specifications, or inspection requirements. Additionally, your firm’s Work Instruction titled, Complete and Document Inspection of Machined Product at Sarasota- Machining 701-105-945 Rev. D, also does not clearly or explicitly outline the production and processing controls or provide step-by-step directions for the required, in-process inspections of the Equinoxe Shoulder Liner device, including specific instructions, equipment needed, process or product parameters or specifications, or inspection requirements. Neither of these Work Instructions document specific instruction on how to perform this inspection test, such as use of the (b)(4) tool, and operator (b)(4) is not addressed. Furthermore, no Operational Qualification was documented for (b)(4) machining processes, of the Equinoxe Polyethylene Shoulder Liner device and devices do not undergo (b)(4) in-process or final testing.\nYour firm’s responses are not adequate. The responses note that the root causes and contributing factors of the process control deficiencies include inconsistent enforcement of validation requirements, gaps in operator training on comparator-based inspections, and absence of formal inspection method qualification. In addition, the responses note that these deficiencies have systemic implications across your firm’s manufacturing operations and as well design transfer activities. Your firm’s responses describe corrections that include a manufacturing and process hold, (b)(4) inspection of existing inventory during process hold and a Field Action for (b)(4) Humeral Shoulder Liners. Your responses also describe corrective and preventative actions under CAPA 2025-30 that include: validation remediation for relevant manufacturing processes across Sarasota and Gainesville; SOP and work instruction redesign and training; inspection method qualification and retention of coordinate measuring machine reports; develop layered process audit work instructions and integration into QMS trending; SOP update for initial out of specification handing; and design transfer and process validation readiness. Your firm’s responses do not describe, and list remediation activities or products associated to legacy design transfer issues across manufacturing operations at your Sarasota and Gainesville facilities. The activities under CAPA 2025-30 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\n2) Failure to adequately establish and maintain procedures for corrective and preventative action, as required by 21 CFR 820.100(a). For example:\nA. The procedure for Corrective and Preventive Actions Procedure, 701-103-137, Rev. AB, dated 6\u002F11\u002F2025 does not identify production events as nonconformities or quality data. A Production Event (PE) is defined as an event generated in (b)(4) utilized for processing electronic device history records, due to a deviation from pre-established product or process specifications. Production Events ((b)(4) documented events) are not analyzed as quality data sources or escalated to CAPAs where appropriate. Investigators noted that from 07\u002F01\u002F2023 to 7\u002F25\u002F2025 there was incomplete documentation maintained or available to demonstrate which Production Event entries were documented and managed as nonconformances. Additionally, no documentation was maintained or available to demonstrate that any Production Events were further assessed or analyzed as quality data sources.\nB. CAPAs 2023-005 and 2025-005 addressing environmental control specifications for (b)(4) storage were verified as effective and closed, yet environmental monitoring data from March 2024 to current showed your firm continued to exceed allowable temperature and humidity limits. Temperature specifications were changed from (b)(4) to (b)(4) in June 2025 after historical data showed consistent excursions. The pFMEA for the (b)(4) Molding Process, FMEA-000445, Rev A, dated 8\u002F1\u002F2024, discusses product and process impact with high temperatures and humidity, and the potential failures related to air conditioning (HVAC). Specifically, the effect of high moisture in (b)(4) may impact the material strength.\nYour firm’s responses are not adequate. Your firm’s responses note corrective actions under CAPA 2025-31 that include: CAPA procedural updates for verification of effectiveness; updates to Quality System’s governance and Management Review process adding additional sources of quality data (Production Events, Work in Process Scrap , environmental monitoring data, etc.); updates to software validation to include evaluation for the identification of critical to quality attributes for continuous monitoring; updates to Document Control related to the QMS process change and the determination of quality data outputs for continuous monitoring; and CAPA remediation efforts for verification of effectiveness. Your responses do not describe any retrospective review necessary to assess whether quality data such as Production Events, Work in Process Scrap, etc. or other critical to quality data attributes represent nonconformances or other quality issues that may require the initiation of a CAPA. The activities under CAPA 2025-31 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\n3) Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example, your firm failed to identify, document, evaluate nonconforming product including the need for investigation and notification of the persons or organizations responsible.\nA. There was no written procedure for handling “Production Events (PE)” identified during manufacturing. The Nonconforming Product Handling Procedure, 701-103-013 Rev. AK, dated 9\u002F13\u002F2024, does not include a process to elevate Production Events to a nonconformance, despite the potential for rework may occur. Production Event entries included those for multiple inspection failures found at various stages in the manufacturing process (in-process inspection and QC inspection). For example:\n1. Failure of product’s dimensional specifications ((b)(4) failure, (b)(4) failure, (b)(4) failure, (b)(4) radius) that may correlate with high scrap rates for dimensional defects.\n2. Surface quality defects that include those for molding contamination: inclusions on articulating surface and mold marks.\n3. Machining process issues from setup and tooling that may create recurring dimensional problems (undersize stems on “(b)(4)”, undersized pin head, undersize due to a fixture issue, damaged threads, smooth and inconsistent threads, burrs in threads).\n4. Packaging issues that include wrinkles on seal, crease in seal, cuts in bag, score mark, seal integrity, loss in vacuum, nonuniform seal, loose fibers and black particles, hair, black particles embedded in bag.\nB. The WIP Scrap Events Collection procedure does not define threshold levels for when internal WIP scrap should be documented as nonconformances. While supplier receiving inspection has defined thresholds ((b)(4) defect rate), no similar thresholds exist for internal operations. Scrap log includes entries for nonconforming product associated with manufacturing process control deficiencies which include:\n1. Machining setup issues where numerous entries are labeled as set up, \"setup part,\" \"dial in\" and tooling\u002Ffixture issues labeled as \"tool broke,\" “bad mold tool”, \"worn tool,\" \"loose tool” and “wrong offset” resulting in scrap from dimensional and product quality problems (button height, overall thickness, overall length, thread noting dings and dents).\n2. Molding process issues resulting in scrap from:\ni. Equipment power issues labeled as “power outage”, “power failure”, “press failure”, “power turned off”;\nii. Hydraulic issues (hydraulic Hit\u002Floss, pressure drop);\niii. Heating and cooling failure (pumps not turned on);\niv. Manufacturing process control issues (“wrong recipes”, “tool not set up”, “missfil”, “not properly blowing out”) resulting in scrap from “flash leakage”, “inclusions on surface” and “under\u002Fover” weight product\n3. Product finishing issues from “over polishing”, “over blasting” and “thread chip wrap” resulting in nonconforming product dispositioned as scrap.\n4. Operator training issues as “operator error” entries for the machining, molding and finishing manufacturing processes resulting in dimensional and cosmetic nonconforming product dispositioned as scrap.\nYour firm’s responses are not adequate. Your firm’s responses note that corrective actions under CAPA 2025-31 that included: the coordination of the nonconformance program with the Production Events (PE) and work in process (WIP), and training development. Your firm’s retrospective review of WIP and PE does not include the rationale for timeframes selected. For example, you identified July 2024 through August 2025 for retrospective review; however, FDA investigators reviewed WIP and PE data from 7\u002F01\u002F2023 through 7\u002F25\u002F2025. In addition, we disagree with your investigation that raw data and pivot tables for Production Events and WIP Scrap entries revealed that the vast majority ((b)(4)) of Production Events were benign in nature, and resolved via appropriate mechanisms (e.g. (b)(4), (b)(4) fix, and approved reworks). Additionally, it is not clear from production event logs collected during the inspection how the in process and quality control inspection failures were handled.\nYour firm notes that although there were gaps in the inconsistent classification and escalation of quality events, that the nonconformances do not indicate a risk to product. FDA disagrees with this assessment in that this does represent a potential risk to distributed product since the FDA inspection and your firm’s investigation identified gaps with QC work instructions and training. Specifically, (b)(4) in-process inspection using manual (b)(4) and (b)(4) lacked formal work instruction to define the method, criteria, or documentation required. This created variability in execution and no documented evidence of consistency or repeatability. Your firm’s CAPA Review Board (CRB) identified this as a systemic breach of regulatory and QMS requirements; however, the assessment noted that it did not require a reportable field action. FDA remains concerned with the potential distribution of nonconforming product.\nThe activities under CAPA 2025-31 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\n4) Failure to adequately establish and maintain procedures to ensure that environmental conditions do not adversely affect product quality, as required by 21 CFR 820.70(c). For example, your firm failed to adequately establish procedures to ensure your environmental controls are being maintained as specified and that your environmental control systems are adequate and functional.\nA. (b)(4) Raw Material Storage, QWI-000185, Rev A, dated 4\u002F30\u002F2024 and the current procedure, Rev B, dated 6\u002F10\u002F2025 were not followed for backup environmental monitoring when the (b)(4) system fails in the Sarasota Molding Facility. (b)(4) system graphs from March 2024 to July 2025 of both temperatures and relative humidity levels were commonly and routinely recorded to be outside of the specified, nominal limit levels.\nB. A Deviation\u002FChange Request, dated 05\u002F27\u002F2025, was “Due to a faulty environmental monitoring sensor ((b)(4)) located in the controlled environment fill room, the sensor will be unplugged, and environmental monitoring will occur using a calibrated data logger for both temperature and humidity”. Only one of (b)(4) poly fill rooms is monitored by the (b)(4) system, with assumption that (b)(4) rooms maintain same conditions despite physical wall separation.\nThe adequacy of your firm’s responses cannot be determined at this time. Your responses note that corrective and preventative actions under CAPA 2025-033 included the environmental monitoring system enhancements; procedural revision to environmental monitoring excursion; training; updates to risk documents; new procedure to be used to document the facility modification; and defining environmental conditions of (b)(4) resin and molded components. The activities under along CAPA 2025-033 with the verification of effectiveness criteria, are in progress and extend through March 2026\n5) Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example, your firm failed to follow the procedures for Supplier Quality Management, 701-103-077, Rev AH, dated 10\u002F31\u002F2023. The FDA investigators noted that (b)(4)., the sole supplier of critical (b)(4) powder, has not received a required on-site audit per Supplier Quality Management Procedure Section 5, Step F, Item 2.C. The last supplier evaluation was conducted in September 2020, with no reevaluation when current procedures were implemented in October 2023. Additionally, there is no signed quality agreement as required per the procedure Section V, Step C, item 4.\nYour firm’s pFMEAs for the (b)(4) molded products document considers the raw (b)(4) powder, a critical component of the processing and quality of the finished devices. In the Process FMEA Process Failure Mode and Effects Analysis (b)(4) Compression Molding Process, FMEA-000445 Rev. A, DCRTC-00194, dated 8\u002F1\u002F2024 notes that if the (b)(4) is not properly received from the supplier and in conformance with the specifications, this could potentially lead to product impact with quality failures, incorrect traceability, higher product scrap or degraded mechanical characteristics.\nThe FDA inspection noted that there were no records to demonstrate that your (b)(4) powder supplier, has or is maintaining environmental controls and storage conditions of the supplied (b)(4) powder component. The current lot of (b)(4) powder in use by your firm, lot number (b)(4), was first qualified in 2021, and all (b)(4) powder received since then, have been identified with the same lot identification. Documentation demonstrates the initial qualification of lot (b)(4) in 2021; however, your firm has received approximately (b)(4) shipments of the same lot of (b)(4) powder from (b)(4), since 2021 to 7\u002F25\u002F2025.\nThe adequacy of your responses cannot be determined at this time. Your responses note the following activities being handled under CAPA2025-034: Supplier Quality Management SOP revision; the reevaluation of approved suppliers; the integration of supplier checks into design transfer activities; revise On-Site Audits and initiate Quality Agreements and On-Site Audits; and initiate Quality Agreements of (b)(4) powder. Many of the activities under CAPA2025-034 along with the verification of effectiveness criteria, are in progress and extend through June 2026. Therefore, we cannot determine the adequacy at this time.\n6) Failure to adequately establish procedures for identifying training needs and ensuring that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b). For example, your firm failed to capture the training of employees as described in the Competency and Training Procedure, 701-103-087, Rev. AB, dated 7\u002F9\u002F2024. FDA inspection noted that:\nA. (b)(4) employees working in manufacturing did not have required QC inspection tools documented in their training records, not meeting the requirement that employees perform all necessary training prior to task execution without oversight.\nB. The procedure states that all retraining shall be documented and recorded as part of the employee’s training record. In the review of 11 nonconformance reports, 7 nonconformance reports identified operator error as the root cause. Retraining was not identified as an action item in 6 of 7 of the reports reviewed.\nYour firm’s responses are not adequate. Your responses note the following activities being handled under CAPA 2025-035 include implementation of Task-Level Training Controls; development of work instructions and inspection tools; documented on the job training; the revision of Nonconforming Product Handling Procedure to enforce training; and revision of competency and training procedure. Your firm’s response does not describe any necessary training as part of the design transfer activities associated to a new manufacturing or inspection process. The activities under CAPA 2025-035 along with the verification of effectiveness criteria, are in progress and extend through April 2026.\n7) Failure to adequately establish procedures for acceptance activities, as required by 21 CFR 820.80(a). For example:\nA. Your firm failed to identify the correct work instructions that applies to manufacturing personnel when using (b)(4) to produce products for the Truliant Knee 02-029-190-4300 Short Headed Pin For Syringe Pin Puller, Alteon Hip 180-165-20 Alteon 6.5MM Screw, 20MM, and the Equinoxe Shoulder Torque Defining Screws. The work instructions listed did not call out for manufacturing personnel to use the Manufacturing of Product in (b)(4) Work Instruction, 701-105-1121, Rev D, effective date 2\u002F28\u002F2024. The work instructions are:\n1. Machining of Holding Pins at Sarasota- Machining Work Instruction 701-105-929, Rev. H, effective date 7\u002F15\u002F2025\n2. Machining of 6.5mm Alteon Cancellous Bone Screw at Sarasota-Machining and Finishing Work Instruction, 701-105-964, Rev. C, effective date 6\u002F22\u002F2021\n3. Manufacturing of Torque Defining Screws at Sarasota-Machining and Finishing Work Instruction, 701-105-1071, Rev B, effective date 11\u002F05\u002F2021\nB. Your firm failed to establish procedures or work instructions for two critical QC inspection tools used for the (b)(4) inspection process for the Equinoxe torque defining screw devices and for the (b)(4) inspection process for the Equinoxe shoulder liner device.\nThe adequacy of your responses cannot be determined at this time. Your responses note that the following activities are being handled under CAPA 2025-036: updates on work instructions that support (b)(4)-controlled tasks and inspection operations; develop inspection tools and work instruction in conjunction with CAPA 2025-35; and work instruction impact review across similar product. The activities under CAPA 2025-036 along with the verification of effectiveness criteria, are in progress and extend through March 2026.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 720250” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.padilla@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Christine Thomas, Chief Quality, Clinical and Regulatory Officer, christine.thomas@advita.com","Exactech, Inc. dba Advita Ortho","exactech-inc-dba-advita-ortho-720250-12192025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexactech-inc-dba-advita-ortho-720250-12192025","2026-10-26T08:08:38.038057+00:00","2026-03-10","720250","Aurelio Sahagun","2026-08-19T04:51:37.735+00:00","2025-12-19",{"id":68,"raw":69,"subject":75,"body_html":76,"body_text":77,"firm_name":78,"letter_id":79,"created_at":80,"fei_number":19,"letter_url":81,"updated_at":82,"action_type":22,"case_status":23,"posted_date":83,"marcs_cms_no":19,"product_type":84,"closeout_date":19,"issuing_office":73,"recipient_name":85,"body_fetched_at":86,"delivery_method":87,"recipient_title":19,"reference_number":88,"action_taken_date":89,"medical_device_id":19,"response_letter_date":19},1305,[70,71,72,73,74,13,13,13],"\u003Ctime datetime=\"2024-08-27T13:20:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-28T04:00:00Z\">06\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fberkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo\">Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 676984\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mesfin Mengesha\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>880 Harbour Way S., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richmond\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 28, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mengesha:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Berkeley Biologics, LLC, (operating during the inspection as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.), located at 880 Harbour Way S., Suite 100, Richmond, CA 94804, conducted between September 05, 2023 and September 25, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of viable bone matrix products derived from human bone tissue and marketed as Viable Bone Matrix (VBM), Fiber Viable Bone Matrix (FVBM), Cellular Fiber Matrix (CFM)\u002FExcel Viable Bone Matrix (EFM),\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and Osteo Viable Bone Matrix (OVM). You have distributed these products throughout the United States to medical facilities. You intend these products to be used in orthopedic or reconstructive bone grafting procedures for bone repair and regeneration, and you purport them to be sterile.\u003C\u002Fp>\n\n\u003Cp>Human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and\u002For the Public Health Service Act (PHS Act) [42 U.S.C. § 262], and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Your products do not qualify for any exception in 21 CFR 1271.15, and your VBM, CFM\u002FEFM, and OVM products fail to meet all the criteria in 21 CFR 1271.10(a). Specifically, VBM, CFM\u002FEFM, and OVM fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of cartilage relating to its utility to perform its load-bearing and other physical functions, which generally include firmness, smoothness, flexibility, and resistance to deformation.\u003C\u002Fp>\n\n\u003Cp>Your products also fail to meet the criterion under 21 CFR 1271.10(a)(3) that the manufacture of the HCT\u002FP does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent. Your VBM, CFM, and OVM products are a combination of bone (cancellous and cortical) and another article, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Therefore, these three products – VBM, CFM\u002FEFM, and OVM – are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because these products do not meet all the criteria in 21 CFR 1271.10(a), and you do not qualify for any exception in 21 CFR 1271.15, these products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\u003C\u002Fp>\n\n\u003Cp>Be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR 312]. None of your products are the subject of an approved BLA, nor is there an IND in effect for any of them. Based on our review, these products are unapproved new drugs that you are introducing or delivering for introduction into interstate commerce in violation of sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act and section 351(a)(1) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented significant deviations from current good tissue practice (CGTP) requirements, including deviations from 21 CFR 1271, for FVBM and OVM. Upon further review of information collected during the inspection, FDA also identified significant deviations from current good manufacturing practice (CGMP) requirements for VBM, CFM\u002FEFM, and OVM, including section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP requirements, your VBM, CFM\u002FEFM, and OVM drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)], your introduction or delivery for introduction into interstate commerce of these three drug products is a prohibited act.\u003C\u002Fp>\n\n\u003Cp>Your CGTP deviations for your FVBM and OVM products manufactured between January 2022 and June 2023, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> For example, you failed to determine as ineligible \u003Cstrong>(b)(4)\u003C\u002Fstrong> deceased donors who have a documented medical diagnosis of sepsis. As discussed in the 2007 \u003Cem>Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs)\u003C\u002Fem> (2007 DE Guidance), donor screening to reduce the risk of transmission of disease agents associated with sepsis is required. Tissues from these donors were manufactured into FVBM and OVM, and distributed for implantation into patients\u002Frecipients, some of which were associated with an outbreak of \u003Cem>Mycobacterium tuberculosis\u003C\u002Fem> infections. It appears this is a systemic issue not limited to these \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors or products because this violation resulted from you following your SOP-0006 \u003Cem>Donor Eligibility Determination Criteria\u003C\u002Fem>, which does not require you to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, sepsis.\u003C\u002Fp>\n\n\u003Cp>We have received and reviewed your written responses, dated October 14, 2023, and November 30, 2023, to FDA’s inspectional observations on the Form FDA-483. The corrective actions described in your response are not adequate to address the above noted violation that was on the FDA-483.\u003C\u002Fp>\n\n\u003Cp>In your October response, you provided your revised procedure, \u003Cem>SOP-006 Donor Eligibility Determination Criteria\u003C\u002Fem> (as Attachment 2.2). Your “Donor Screening Guidance Document” in Attachment 2.2 and the revised sepsis algorithm in SOP-0006 do not determine as ineligible, donors who have a documented medical diagnosis of sepsis. Sepsis is a relevant communicable disease agent and disease (RCDAD) under 1271.3(r)(2), as described in the 2007 DE Guidance. Under 1271.75(d)(1), you must determine as ineligible a donor who is identified as having a risk factor for or clinical evidence of any RCDAD. You should revise Berkeley’s Donor Screening Guidance Document for sepsis and revise your sepsis algorithm in SOP-0006 so that these documents are compliant with 1271.75(d)(1).\u003C\u002Fp>\n\n\u003Cp>This donor eligibility issue applies across your products, including those regulated solely under section 361 of the PHS Act. Based on information available to FDA, you have received tissues from at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors who have sepsis documented in their medical records. We request that you provide us a list of all donors that have had risk factors for or clinical evidence of sepsis that you have determined to be eligible along with the products you have manufactured and distributed from these donors.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deviations for VBM, CFM\u002FEFM, and OVM manufactured between January 2022 and June 2023, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\n\n\u003Cp>a. According to your Process Qualification Reports (dated January 17, 2017, March 16, 2020, and April 7, 2023), you only required \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors to meet your process qualification acceptance criteria even if some donor batches in the validation\u002Fqualification failed to meet the criteria. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> OVM donor batches failed to meet your acceptance criteria, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> donor batches failed to meet your acceptance criteria for sterility testing.\u003C\u002Fp>\n\n\u003Cp>b. You have not validated the manufacturing processes for VBM, CFM\u002FEFM, and OVM with respect to identity, strength, quality, and purity. Your Process Qualification Reports document product bioburden testing, sterility testing, environmental and personnel monitoring, and in some cases \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, as the only tests included in your acceptance criteria. These tests are inadequate to assure the identity, strength, quality, and purity of these products.\u003C\u002Fp>\n\n\u003Cp>Based on our review of the “retrospective validation addendums” you provided in your November 2023 response, you have not addressed the issues noted above. For example, your validations continue to focus on sterility assurance controls, rather than identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system necessary to prevent contamination or mix-ups during aseptic processing [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your action limits for microbiological monitoring (i.e., active viable air and surface samples) within the critical area (i.e., inside the Biological Safety Cabinet (BSC)) were observed to be greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs). Such high numbers of microorganisms can contribute to product contamination and pose a potentially significant safety concern.\u003C\u002Fp>\n\n\u003Cp>b. You do not perform sampling of critical surfaces in the BSC for microorganisms in association with each production batch.\u003C\u002Fp>\n\n\u003Cp>c. Your personnel monitoring sample locations are inadequate for personnel performing aseptic processing. For example, your firm does not conduct personnel monitoring of the forearms\u002Fsleeves of operators working in the BSC where your products are aseptically processed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish laboratory controls that include scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not established scientifically sound and appropriate specifications and test procedures to assure that VBM, CFM\u002FEFM, and OVM conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, which is inadequate to measure appropriate standards of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. Sterility samples of VBM, CFM\u002FEFM, and OVM are frozen prior to sterility testing. Freezing product has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\u003C\u002Fp>\n\n\u003Cp>In your responses, you have committed to stopping the manufacture and distribution of all viable bone matrix products until, you state, you have met, “FDA’s standards for tissue processing validation.” However, you have not addressed the products manufactured under the violative conditions described above that remain on the market and available for implantation nor have you addressed the above CGMP violations. We acknowledge that the above CGMP violations were not included in the FDA-483; we expect you to address them in response to this letter.\u003C\u002Fp>\n\n\u003Cp>Additionally, your response fails to address your failure to have an IND in effect to study your VBM, CFM\u002FEFM, and OVM products or your lack of an approved BLA to lawfully market these products.\u003C\u002Fp>\n\n\u003Cp>Please also be advised that FDA has conducted a preliminary review of your HCT\u002FP, Fiber Viable Bone Matrix (FVBM). Based on the limited information available to FDA, we do not have a basis at this time for concluding that the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271 are met for Berkeley Biologics’ FVBM allogeneic HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment is in full compliance with applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you believe that your products are not in violation of the FD&amp;C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\u003C\u002Fp>\n\n\u003Cp>Your response to this letter should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nKarlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations - Division 2\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\n\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that the product name was changed from Excel Fiber Matrix to Cellular Fiber Matrix on April 21, 2023.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nOBPO 676984\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMesfin Mengesha\n\nRecipient Title\n\nChief Executive Officer\n\nBerkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\n\n880 Harbour Way S., Suite 100\n\nRichmond, CA 94804\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nJune 28, 2024\n\nDear Mr. Mengesha:\n\nDuring an inspection of your firm, Berkeley Biologics, LLC, (operating during the inspection as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.), located at 880 Harbour Way S., Suite 100, Richmond, CA 94804, conducted between September 05, 2023 and September 25, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of viable bone matrix products derived from human bone tissue and marketed as Viable Bone Matrix (VBM), Fiber Viable Bone Matrix (FVBM), Cellular Fiber Matrix (CFM)\u002FExcel Viable Bone Matrix (EFM),1 and Osteo Viable Bone Matrix (OVM). You have distributed these products throughout the United States to medical facilities. You intend these products to be used in orthopedic or reconstructive bone grafting procedures for bone repair and regeneration, and you purport them to be sterile.\n\nHuman cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and\u002For the Public Health Service Act (PHS Act) [42 U.S.C. § 262], and are subject to additional regulation, including appropriate premarket review.\n\nYour products do not qualify for any exception in 21 CFR 1271.15, and your VBM, CFM\u002FEFM, and OVM products fail to meet all the criteria in 21 CFR 1271.10(a). Specifically, VBM, CFM\u002FEFM, and OVM fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of cartilage relating to its utility to perform its load-bearing and other physical functions, which generally include firmness, smoothness, flexibility, and resistance to deformation.\n\nYour products also fail to meet the criterion under 21 CFR 1271.10(a)(3) that the manufacture of the HCT\u002FP does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent. Your VBM, CFM, and OVM products are a combination of bone (cancellous and cortical) and another article, (b)(4).\n\nTherefore, these three products – VBM, CFM\u002FEFM, and OVM – are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because these products do not meet all the criteria in 21 CFR 1271.10(a), and you do not qualify for any exception in 21 CFR 1271.15, these products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\n\nBe advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR 312]. None of your products are the subject of an approved BLA, nor is there an IND in effect for any of them. Based on our review, these products are unapproved new drugs that you are introducing or delivering for introduction into interstate commerce in violation of sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented significant deviations from current good tissue practice (CGTP) requirements, including deviations from 21 CFR 1271, for FVBM and OVM. Upon further review of information collected during the inspection, FDA also identified significant deviations from current good manufacturing practice (CGMP) requirements for VBM, CFM\u002FEFM, and OVM, including section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP requirements, your VBM, CFM\u002FEFM, and OVM drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)], your introduction or delivery for introduction into interstate commerce of these three drug products is a prohibited act.\n\nYour CGTP deviations for your FVBM and OVM products manufactured between January 2022 and June 2023, include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. For example, you failed to determine as ineligible (b)(4) deceased donors who have a documented medical diagnosis of sepsis. As discussed in the 2007 Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs) (2007 DE Guidance), donor screening to reduce the risk of transmission of disease agents associated with sepsis is required. Tissues from these donors were manufactured into FVBM and OVM, and distributed for implantation into patients\u002Frecipients, some of which were associated with an outbreak of Mycobacterium tuberculosis infections. It appears this is a systemic issue not limited to these (b)(4) donors or products because this violation resulted from you following your SOP-0006 Donor Eligibility Determination Criteria, which does not require you to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, sepsis.\n\nWe have received and reviewed your written responses, dated October 14, 2023, and November 30, 2023, to FDA’s inspectional observations on the Form FDA-483. The corrective actions described in your response are not adequate to address the above noted violation that was on the FDA-483.\n\nIn your October response, you provided your revised procedure, SOP-006 Donor Eligibility Determination Criteria (as Attachment 2.2). Your “Donor Screening Guidance Document” in Attachment 2.2 and the revised sepsis algorithm in SOP-0006 do not determine as ineligible, donors who have a documented medical diagnosis of sepsis. Sepsis is a relevant communicable disease agent and disease (RCDAD) under 1271.3(r)(2), as described in the 2007 DE Guidance. Under 1271.75(d)(1), you must determine as ineligible a donor who is identified as having a risk factor for or clinical evidence of any RCDAD. You should revise Berkeley’s Donor Screening Guidance Document for sepsis and revise your sepsis algorithm in SOP-0006 so that these documents are compliant with 1271.75(d)(1).\n\nThis donor eligibility issue applies across your products, including those regulated solely under section 361 of the PHS Act. Based on information available to FDA, you have received tissues from at least (b)(4) donors who have sepsis documented in their medical records. We request that you provide us a list of all donors that have had risk factors for or clinical evidence of sepsis that you have determined to be eligible along with the products you have manufactured and distributed from these donors.\n\nYour CGMP deviations for VBM, CFM\u002FEFM, and OVM manufactured between January 2022 and June 2023, include, but are not limited to, the following:\n\n2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example,\n\na. According to your Process Qualification Reports (dated January 17, 2017, March 16, 2020, and April 7, 2023), you only required (b)(4) donors to meet your process qualification acceptance criteria even if some donor batches in the validation\u002Fqualification failed to meet the criteria. For example, (b)(4) of (b)(4) OVM donor batches failed to meet your acceptance criteria, and (b)(4) of the (b)(4) donor batches failed to meet your acceptance criteria for sterility testing.\n\nb. You have not validated the manufacturing processes for VBM, CFM\u002FEFM, and OVM with respect to identity, strength, quality, and purity. Your Process Qualification Reports document product bioburden testing, sterility testing, environmental and personnel monitoring, and in some cases (b)(4) testing, as the only tests included in your acceptance criteria. These tests are inadequate to assure the identity, strength, quality, and purity of these products.\n\nBased on our review of the “retrospective validation addendums” you provided in your November 2023 response, you have not addressed the issues noted above. For example, your validations continue to focus on sterility assurance controls, rather than identity, strength, quality, and purity.\n\n3. Failure to have an adequate system necessary to prevent contamination or mix-ups during aseptic processing [21 CFR 211.42(c)(10)(iv)]. For example:\n\na. Your action limits for microbiological monitoring (i.e., active viable air and surface samples) within the critical area (i.e., inside the Biological Safety Cabinet (BSC)) were observed to be greater than (b)(4) colony forming units (CFUs). Such high numbers of microorganisms can contribute to product contamination and pose a potentially significant safety concern.\n\nb. You do not perform sampling of critical surfaces in the BSC for microorganisms in association with each production batch.\n\nc. Your personnel monitoring sample locations are inadequate for personnel performing aseptic processing. For example, your firm does not conduct personnel monitoring of the forearms\u002Fsleeves of operators working in the BSC where your products are aseptically processed.\n\n4. Failure to establish laboratory controls that include scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\n\na. You have not established scientifically sound and appropriate specifications and test procedures to assure that VBM, CFM\u002FEFM, and OVM conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, which is inadequate to measure appropriate standards of identity, strength, quality, and purity.\n\nb. Sterility samples of VBM, CFM\u002FEFM, and OVM are frozen prior to sterility testing. Freezing product has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\n\nIn your responses, you have committed to stopping the manufacture and distribution of all viable bone matrix products until, you state, you have met, “FDA’s standards for tissue processing validation.” However, you have not addressed the products manufactured under the violative conditions described above that remain on the market and available for implantation nor have you addressed the above CGMP violations. We acknowledge that the above CGMP violations were not included in the FDA-483; we expect you to address them in response to this letter.\n\nAdditionally, your response fails to address your failure to have an IND in effect to study your VBM, CFM\u002FEFM, and OVM products or your lack of an approved BLA to lawfully market these products.\n\nPlease also be advised that FDA has conducted a preliminary review of your HCT\u002FP, Fiber Viable Bone Matrix (FVBM). Based on the limited information available to FDA, we do not have a basis at this time for concluding that the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271 are met for Berkeley Biologics’ FVBM allogeneic HCT\u002FP.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment is in full compliance with applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you believe that your products are not in violation of the FD&C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\n\nYour response to this letter should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations - Division 2\n\ncc:\n\n(b)(6), (b)(7)(C)\n\n____________________\n\n1 We note that the product name was changed from Excel Fiber Matrix to Cellular Fiber Matrix on April 21, 2023.","Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.","berkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fberkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo","2026-10-26T08:08:03.464886+00:00","2024-08-27","Biologics","Mesfin Mengesha","2026-08-19T23:52:08.617+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","OBPO 676984","2024-06-28",4,{"510k":92,"classification":93,"enforcement":94,"event":95,"event_backfill":96,"pma":97,"warning_letter":98},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]